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METHODS AND COMPOSITIONS FOR 
POXVIRUS A35R PROTEIN 
STATEMENT OF PRIORITY 
0001. This application is a divisional application of, and 
claims priority to, U.S. patent application Ser. No. 12/281, 
099, filed on Aug. 28, 2008 and issued as U.S. Pat. No. 
8,202,521 on Jun. 19, 2012, which is a 35 U.S.C. S371 
national phase application of PCT International Application 
No. PCT/US2006/007393, filed on Mar. 1, 2006, the entire 
contents of each of which are incorporated by reference 
herein. 
FIELD OF THE INVENTION 
0002 The present invention relates to poxvirus A35R pro 
tein, antibodies thereto, and nucleic acids encoding the A35R 
protein and their use in diagnostic and therapeutic methods. 
BACKGROUND ART 
0003 Poxviruses are large double-stranded DNA viruses 
with genomes that range from 130 to 379 kbp. Poxviruses 
have worldwide distribution and infect a wide variety of ani 
mals, including insects, birds and mammals. Since the eradi 
cation of smallpox and the cessation of vaccination programs, 
various poxvirus infections have begun to re-emerge clini 
cally worldwide. Variola virus continues to present a bioter 
rorism threat and several other poxviruses infect humans, 
causing morbidity and mortality: molluscum contagiosum 
virus (MCV), monkeypox virus, Tanapox virus, Yaba-like 
disease virus, cowpox virus and Cantagalo virus (evolved 
from a vaccinia virus (VV) vaccine strain). The prevalence of 
poxviruses in animals and humans and their propensity for 
recombination and gene acquisition Suggest that it would be 
unwise to discount them as important human pathogens. This 
is especially true, since most emerging infectious diseases are 
Zoonoses, crossing from animals to humans, and poxviruses 
are known to acquire mutations and become highly patho 
genic in a new animal species. 
0004. The A35R gene is highly conserved in mammalian 
tropic poxviruses. VV is the model poxvirus to study the 
A35R protein (called A35R in Copenhagen strain, O158 in 
WR strain and a number of other designations in all mamma 
lian-tropic poxviruses) and its role in the virus life cycle. The 
present invention provides the discovery that the A35R pro 
tein has immunoregulatory activity. Thus, the present inven 
tion overcomes previous shortcomings in the art by providing 
an A35R protein and biologically active fragments thereof, as 
well as nucleic acids encoding this protein and its fragments 
and antibodies and inhibitors specific thereto. These compo 
sitions are used, for example, in methods of diagnosing, treat 
ing and preventing infection by poxvirus, treating and pre 
venting other disorders and in modulating immune responses. 
SUMMARY OF THE INVENTION 
0005. The present invention provides a method of modu 
lating an immune response in a Subject, comprising adminis 
tering to the Subject an immunomodulating amount of an 
A35R protein or active fragment thereof of vaccinia virus or 
other poxvirus and/or administering an immunomodulating 
amount of a nucleic acid encoding an A35R protein or active 
fragment thereof of vaccinia virus or other poxvirus. 
0006 Further provided herein is a method of treating or 
preventing an autoimmune disorder in a subject, comprising 
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administering to the subject an effective amount of an A35R 
protein or active fragment thereof of vaccinia virus or other 
poxvirus and/or administering an effective amount of a 
nucleic acid encoding an A35R protein or active fragment 
thereof of vaccinia virus or other poxvirus. 
0007. In addition, the present invention provides a method 
of reducing the likelihood of transplant rejection in a trans 
plant recipient, comprising administering to the Subject an 
effective amount of an A35R protein or active fragment 
thereof of vaccinia virus or other poxvirus and/or administer 
ing an effective amount of a nucleic acid encoding an A35R 
protein or active fragment thereof of vaccinia virus or other 
poxvirus. 
0008 Also included is a method of enhancing an immune 
response to a poxvirus Vaccine in a Subject, comprising 
administering to the Subject an immunogenic amount of a 
poxvirus Vaccine engineered to lack nucleic acid encoding an 
A35R protein and/or to lack A35R protein activity. 
0009. In additional embodiments, the present invention 
provides a method of enhancing an immune response in a 
Subject to a heterologous antigen encoded by a poxvirus 
vector, comprising administering to the Subject an immuno 
genic amount of a poxvirus vector comprising nucleic acid 
encoding the antigen and wherein the poxvirus vector is engi 
neered to lack nucleic acid encoding an A35R protein and/or 
to lack A35R protein activity. 
0010 Furthermore, the present invention provides a 
method of treating or preventing a detrimental immune 
response in a Subject, comprising administering to the Subject 
an effective amount of an A35R protein or active fragment 
thereof of vaccinia virus or other poxvirus protein and/or 
administering an effective amount of a nucleic acid encoding 
an A35R protein or active fragment thereof of vaccinia virus 
or other poxvirus. 
0011. A method is also provided herein of treating or 
preventing a detrimental immune response in a subject 
wherein the detrimental immune response is caused by A35R 
protein activity, comprising administering to the Subject an 
effective amount of a substance that inhibits A35R protein 
activity. 
0012. The present invention further provides a method of 
enhancing an immunomodulating effect of a Substance, com 
prising combining the Substance with an A35R protein or 
active fragment thereof of vaccinia virus or other poxvirus 
and/or combining the Substance with a nucleic acid encoding 
an A35R protein or active fragment thereof of vaccinia virus 
or other poxvirus. 
0013 Additionally provided herein is a method of treating 
or preventing a poxvirus infection in a subject, comprising 
administering to the Subject an effective amount of an inhibi 
tor of A35R protein activity. 
0014 Further embodiments of this invention include a 
method of diagnosing a poxvirus infection in a Subject, com 
prising: a) contacting a sample from the Subject with an 
antibody that specifically binds A35R protein under condi 
tions whereby an antigen/antibody complex can form; and b) 
detecting formation of the antigen/antibody complex, thereby 
diagnosing poxvirus infection in a Subject. 
0015. Also provided herein is a method of diagnosing 
poxvirus infection in a subject, comprising: a) contacting a 
sample from the subject with an A35R protein or antigenic 
fragment thereof under conditions whereby an antigen/anti 
US 2012/O294.896 A1 
body complex can form; and b) detecting formation of the 
antigen/antibody complex, thereby diagnosing poxvirus 
infection in a Subject. 
0016. A method is also provided herein of detecting pox 
virus in a sample, comprising: a) contacting the sample with 
an antibody that specifically binds A35R protein under con 
ditions whereby an antigen/antibody complex can form; and 
b) detecting formation of the antigen/antibody complex, 
thereby detecting poxvirus in the sample. 
0017. Further provided herein is a method of detecting an 
antibody to poxvirus in a sample, comprising: a) contacting 
the sample with an A35R protein or antigenic fragment 
thereof under conditions whereby an antigen/antibody com 
plex can form; and b) detecting formation of the antigen/ 
antibody complex, thereby detecting an antibody to poxvirus 
in the sample. 
0018. In addition, the present invention provides a method 
of identifying nucleic acid comprising a nucleotide sequence 
encoding A35R protein in a sample, comprising: a) contact 
ing the sample with an oligonucleotide comprising a nucle 
otide sequence that is complementary to the nucleotide 
sequence encoding A35R protein, under conditions whereby 
nucleic acid hybridization can occur, and b) detecting nucleic 
acid hybridization, thereby detecting nucleic acid comprising 
the nucleotide sequence encoding A35R protein in the 
sample. 
0019. Additional embodiments include a method of iden 
tifying nucleic acid comprising a nucleotide sequence encod 
ing A35R protein in a sample, comprising: a) contacting the 
sample with a pair of oligonucleotide primers that are 
complementary to the nucleotide sequence encoding A35R 
protein, under conditions whereby nucleic acid amplification 
can occur, and b) detecting nucleic acid amplification, 
thereby detecting nucleic acid comprising the nucleotide 
sequence encoding A35R protein in the sample. 
0020. The present invention additionally provides a 
method of treating cancer in a subject, comprising adminis 
tering to the subject a poxvirus engineered to lack A35R 
protein activity and in some embodiments, the poxvirus can 
further comprise: a) nucleic acid encoding a costimulatory 
molecule (e.g., B7.1, ICAM-1, LFA-3); b) nucleic acid 
encoding a tumor antigen; and/or c) nucleic acid encoding an 
immunomodulatory protein, in any combination. 
0021. In other embodiments, the present invention pro 
vides a composition comprising A35R protein and a pharma 
ceutically acceptable carrier and a composition comprising a 
poxvirus engineered to lack A35R activity and a pharmaceu 
tically acceptable carrier and a composition consisting essen 
tially of a nucleotide sequence encoding a poxvirus A35R 
protein and a pharmaceutically acceptable carrier. 
0022 Various other objectives and advantages of the 
present invention will become apparent from the following 
detailed description. 
DETAILED DESCRIPTION OF THE INVENTION 
0023 The present invention is based on the unexpected 
discovery that the A35R protein of poxvirus has immuno 
modulating activity. Thus, in one embodiment, the present 
invention provides a method of modulating an immune 
response in a subject, comprising administering to the Subject 
an effective amount of an A35R protein or active fragment 
thereof of vaccinia virus or other poxvirus and/or administer 
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ing to the Subject an effective amount of a nucleic acid encod 
ing an A35R protein or active fragment thereof of vaccinia 
virus or other poxvirus. 
0024. Further provided in this invention is a method of 
treating and/or preventing an autoimmune disorder in a Sub 
ject, comprising administering to the Subject an effective 
amount of an A35R protein or active fragment thereof of 
vaccinia virus or other poxvirus and/or administering an 
effective amount of a nucleic acid encoding an A35R protein 
or active fragment thereof of a vaccinia virus or other poxvi 
rus. Nonlimiting examples of autoimmune disorders that can 
be treated and/or prevented by the methods of this invention 
include arthritis (e.g., rheumatoid arthritis or RA), multiple 
Sclerosis (MS), diabetes (e.g., insulin dependent diabetes 
mellitus or IDDM), systemic lupus erythematosus (SLE), 
myasthenia gravis, Crohns' disease, regional enteritis, vascu 
litis, ulcerative colitis, Sjogren's syndrome, ankylosing 
spondylitis, polymyositis and any other autoimmune disorder 
now known or later identified. The methods of the present 
invention can further be employed to treat allergies, allergic 
reactions, and any other disease or disorder associated with an 
aberrant and/or undesirable immune response or reaction. 
0025. Additionally provided is a method of reducing the 
likelihood of transplant rejection (or increasing the likelihood 
of Successful transplantation) in a transplant recipient, com 
prising administering to the transplant recipient an effective 
amount of an A35R protein or active fragment thereof of 
vaccinia virus or other poxvirus and/or administering to the 
transplant recipient an effective amount of a nucleic acid 
encoding an A35R protein or active fragment thereof of vac 
cinia virus or other poxvirus. The reduction in the likelihood 
of transplant rejection or increase in the likelihood of Suc 
cessful transplantation is in comparison to the likelihood of 
transplant rejection or likelihood of Successful transplanta 
tion in a transplant recipient that did not receive an A35R 
protein or active fragment thereof or a nucleic acid encoding 
an A35R protein or active fragment thereof, as such likeli 
hoods would be know and/or determined according to art 
known standards. Furthermore, the protein, active fragment 
and/or nucleic acid of these methods can be administered to 
the transplant recipient at any time relative to the transplan 
tation (i.e., before, after and/or simultaneously, in any com 
bination. 
0026. In additional embodiments of this invention, a 
method is provided of enhancing an immune response to a 
poxvirus vaccine in a subject, comprising administering to 
the Subject an immunogenic amount of a poxvirus-vaccine 
engineered to lack nucleic acid encoding an A35R protein 
and/or to lack A35R protein activity. Thus, the poxvirus used 
in the vaccine can have a complete or partial deletion of the 
nucleotide sequence encoding the A35R protein or the pox 
virus of the vaccine can have an alteration in the nucleotide 
sequence encoding the A35R protein (e.g., a deletion, Substi 
tution, insertion, stop codon, missense mutation, nonsense 
mutation, or any other mutation), the end result being a lack of 
A35R protein activity in a cell or subject to which the poxvi 
rus vaccine has been delivered or introduced. Nonlimiting 
examples of poxviruses that can be altered according to the 
methods of this invention to lack A35R protein activity are the 
attenuated Modified Vaccinia Ankara (MVA) vaccine, the 
DRYVAX vaccine, the Acambis vaccines (ACM1000 and 
ACM2000), as well as any other poxvirus vaccine now known 
or later identified. 
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0027. Also provided herein is a method of enhancing an 
immune response in a Subject to a heterologous antigen 
encoded by a poxvirus vector, comprising administering to 
the Subject an immunogenic amount of a poxvirus vector 
comprising nucleic acid encoding the antigen and wherein the 
poxvirus vectoris engineered to lack nucleic acid encoding an 
A35R protein and/or to lack A35R protein activity. As noted 
above, the poxvirus used in the vaccine can have a complete 
or partial deletion of the nucleotide sequence encoding the 
A35R protein or the poxvirus of the vaccine can have an 
alteration in the nucleotide sequence encoding the A35R pro 
tein (e.g., a deletion, Substitution, insertion, top codon, mis 
sense mutation, nonsense mutation, or any other mutation), 
the end result being a lack of A35R protein activity in a cellor 
subject to which the poxvirus vaccine has been delivered or 
introduced. The use of poxviruses as vectors to deliver anti 
gens for vaccine is known in the art. Nonlimiting examples of 
such vectors include those described for rabies vaccines in 
Rupprecht et al. (Virus Research 111:101-105 (2005)); HIV 
vaccines in Cebere et al. (Vaccine 24:417-425 (2006)); tuber 
culosis vaccines in Xing et al. (Curr. Gene Ther: 5:485-482 
(2005)); and for cancer immunotherapies in Kaufman et al. 
(Curr. Gene Ther: 17:239-244 (2006)). 
0028. In the methods provided herein for enhancing an 
immune response, such an enhancement is identified by com 
parison with an immune response in a Subject that did not 
receive the protein, active fragment and/or nucleic acid of this 
invention. Such comparative studies can be carried out 
according to well known protocols in the art for detecting 
and/or measuring any number of immune responses. Nonlim 
iting examples of an immune response that can be enhanced 
by the methods of this invention include antibody response 
(e.g., protective antibody response; neutralizing antibody 
response), cytotoxic T cell response, Thelper response, inter 
leukin-2 (IL-2) production; and vaccine efficacy. 
0029. Further provided herein is a method of treating or 
preventing a detrimental immune response in a subject, com 
prising administering to the Subject an effective amount of an 
A35R protein or active fragment thereof of vaccinia virus or 
other poxvirus protein and/or an effective amount of a nucleic 
acid encoding an A35R protein or active fragment thereof of 
a vaccinia virus or other poxvirus. 
0030. Also provided herein is a method of treating or 
preventing a detrimental immune response in a subject 
wherein the detrimental immune response is caused by A35R 
protein activity, comprising administering to the Subject an 
effective amount of a substance that inhibits A35R protein 
activity. A substance that inhibits A35R activity, can be, but is 
not limited to a ligand (e.g., an antibody or antibody frag 
ment) that specifically binds an A35R protein or active frag 
ment thereof and/or a nucleic acid that inhibits transcription 
or translation of nucleic acid encoding an A35R protein or 
active fragment thereof (e.g., an antisense nucleic acid that 
binds a coding sequence of the A35R protein, an interfering 
RNA that inhibits or suppresses transcription and/or transla 
tion of the A35R protein, a ribozyme, etc.) Furthermore, 
Small molecules and other compounds and Substances that 
inhibit the activity of A35R could be used in the methods of 
this invention. 
0031. A detrimental immune response as described herein 
can be, for example, a detrimental immune response pro 
duced by an agent comprising the A35R protein or nucleic 
acid encoding the A35R protein. Examples of a detrimental 
immune response include but are not limited to allergic reac 
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tion or allergy, immune-mediated inflammation of the organs 
(e.g., heart; central nervous system; kidney; liver), pathogen 
induced immunopathology, autoimmune diseases and disor 
ders (e.g., diabetes, SLE, MS), etc. 
0032. In other embodiments of this invention, the detri 
mental immune response can be an immune response pro 
duced by a bioterrorism agent (e.g., an immune response that 
is harmful to a subject that can be modulated by delivery to the 
subject of the A35R protein or active fragment thereof and/or 
nucleic acid of this invention). Examples of such bioterrorism 
agents include but are not limited to infectious biological 
agents such as pathogenic bacteria (e.g., Yersinia causing 
plague; Bacillus anthracia causing anthrax: Francisella tulla 
rensis), viruses (e.g., influenza; SARS coronavirus; Ebola 
virus; Marburg virus), toxins, etc., as well as any other agent 
now known or later identified that can be used as a bioterror 
ism agent. 
0033. In yet other embodiments, the detrimental immune 
response can be produced by the presence, either naturally or 
unnaturally, in the bioterrorism agent, of the A35R protein or 
active fragment thereof or a nucleic acid encoding the A35R 
protein or active fragment thereof. In such embodiments, the 
detrimental immune response is treated by delivery to the 
subject of a substance as described herein that inhibits or 
reduces A35R protein activity. Examples of such bioterrorism 
agents can include Smallpox, vectors comprising A35R activ 
ity and other infectious agents and toxic agents as described 
herein that are engineered to have A35R activity. 
0034. In yet further embodiments of this invention, a 
method is provided of enhancing an immunomodulating 
effect of a substance, comprising combining the Substance 
with an A35R protein or active fragment thereof of vaccinia 
virus or other poxvirus and/or combining the Substance with 
a nucleic acid encoding an A35R protein or active fragment 
thereof. Such a Substance that has an immunomodulating 
effect can be but is not limited to steroids, immunosuppres 
sive drugs, interferons, corticosteroids, azathioprine, cyclo 
phosphamide, prednisone, methotrexate, rituximab, etc., as 
well as any other immunomodulating agent now known or 
later identified. 
0035 An enhancement of an immunomodulating effect of 
a Substance would be identified by comparison of an immu 
nomodulating effect of the Substance in a Subject with and 
without the presence of the A35R protein or active fragment 
thereof or nucleic acid encoding the A35R protein or active 
fragment thereof. As used herein, an “immunomodulating 
effect” is any action or activity of a cell or tissue of the 
immune system. Such an immunomodulating effect can be 
positive or negative, an enhancement or an inhibition, an 
increase or a decrease in a response, activity and/or reaction. 
Ways to detect and/or measure an immunomodulating effect 
are known in the art and include standard protocols such as 
those used to detect and/or measure antibody production or 
activity, T lymphocyte proliferation or activity, cytotoxicity 
and/or cytokine production or activity. 
0036. The present invention additionally provides a 
method of treating or preventing a poxvirus infection in a 
Subject, comprising administering to the Subject an effective 
amount of an inhibitor of A35R protein activity. As noted 
above, a substance that inhibits A35R activity, can be, but is 
not limited to a ligand, an antibody or an antibody fragment 
that specifically binds an A35R protein or active fragment 
thereof, a nucleic acid that inhibits transcription or translation 
of nucleic acid encoding an A35R protein or active fragment 
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thereof and/or a drug or other substance that acts to inhibit 
A35R activity (e.g., immunosuppressive drugs, steroids, 
interferon, etc.) 
0037. The method of treating or preventing infection 
caused by poxvirus in a Subject can be carried out, for 
example, by contacting an immune cell of the Subject with 
any of the polypeptides, fragments, nucleic acids, vectors 
and/or antibodies of this invention. The cell can be, for 
example, a CD8" T cell which is contacted with the polypep 
tide and/or fragment of this invention in the presence of a 
class I MHC molecule, which can be a soluble molecule or it 
can be present on the Surface of a cell which expresses class I 
MHC molecules. The cell can also be any cell that can take up 
and express exogenous nucleic acid and produce the polypep 
tides and/or fragments of this invention. In some embodi 
ments, the polypeptides and/or fragments of this invention 
can be produced by a cell that secretes them, whereby the 
polypeptide and/or fragment is produced and secreted and 
then taken up and Subsequently processed by an antigen pre 
senting cell or other class I MHC-expressing cell and pre 
sented to the immune system for induction of an immune 
response. In other embodiments, the nucleic acids and/or 
vectors of this invention can be directly introduced into an 
antigen presenting cell and/or other class I MHC-expressing 
cell in which the polypeptide and/or fragment is produced and 
processed directly and presented to the immune system on the 
cell surface. 
0038. As set forth above, it is contemplated that in the 
methods wherein the compositions of this invention are 
administered to a subject or to a cell of a Subject, Such meth 
ods can further comprise the step of administering a suitable 
adjuvant to the subject or to a cell of the subject. The adjuvant 
can be in the composition of this invention or the adjuvant can 
be in a separate composition comprising the Suitable adjuvant 
and a pharmaceutically acceptable carrier. The adjuvant can 
be administered prior to, simultaneous with, and/or after 
administration of the composition containing any of the 
polypeptides, fragments, nucleic acids and/or vectors of this 
invention. For example, QS-21, similar to alum, complete 
Freund's adjuvant, SAF, etc., can be administered within 
days/weeks/hours (before or after) of administration of the 
composition of this invention. The effectiveness of an adju 
vant can be determined by measuring the immune response 
directed against the polypeptide and/or fragment of this 
invention with and without the adjuvant, using standard pro 
cedures, as described herein and as are well known in the art. 
0039. The subject of this invention can be any subject in 
need of the immune response of this invention and/or in need 
of treatment for or prevention from poxvirus infection, as well 
as any subject in whom it is desirable to induce an immune 
response topoxvirus. Sucha Subject can be any type of animal 
that is susceptible to infection by a poxvirus of this invention, 
as well as any animal to which the proteins, active fragments 
thereof and nucleic acids of this invention can be adminis 
tered according to the methods of this invention. For example, 
an animal of this invention can be a mammal, a bird or a 
reptile. In certain embodiments, the subject of this invention 
is a human. 
0040 Symptoms of poxvirus infection can include fever, 
headache, muscle and/or joint aches, fever, rash, inflamma 
tion, etc. Appropriate treatment can lead to a reduction in the 
severity of and/or elimination of one or more of these symp 
tOmS. 
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0041. The compositions of this invention can be adminis 
tered to a cell of a subject or to a subject either in vivo or ex 
vivo. For administration to a cell of the subject in vivo, as well 
as for administration to the Subject, the compositions of this 
invention can be administered orally, parenterally (e.g., intra 
venously), by intramuscular injection, by intraperitoneal 
injection, Subcutaneous injection, transdermally, extracorpo 
really, topically or the like. Also, the compositions of this 
invention can be pulsed onto dendritic cells, which are iso 
lated or grown from a subject's cells, according to methods 
well known in the art, or onto bulk peripheral blood mono 
nuclear cells (PBMC) or various cell subfractions thereof 
from a subject. 
0042. The exact amount of the composition required will 
vary from Subject to Subject, depending on the species, age, 
weight and general condition of the Subject, the particular 
composition used, its mode of administration and the like. 
Thus, it is not possible to specify an exact amount for every 
composition of this invention. However, effective amount can 
be determined by one of ordinary skill in the art using only 
routine experimentation given the teachings herein. 
0043. As an example, to a subject diagnosed with poxvirus 
infection or known to be at risk of being infected with pox 
virus or in whom it is desirable to induce an immune response 
to poxvirus, between about 0.1 g/kg to about 10 g/kg of a 
polypeptide and/or biologically active fragment of this inven 
tion can be administered Subcutaneously and can be in an 
adjuvant, at hourly, daily and/or weekly intervals until an 
evaluation of the Subject's clinical parameters indicate that 
the subject is recovered from infection by poxvirus and/or the 
Subject demonstrates the desired immunological response. 
Alternatively, a polypeptide and/or fragment of this invention 
can be pulsed onto dendritic cells at a concentration of 
between about 0.1 ng to about 500 mg and the dendritic cells 
can be administered to the Subject intravenously at the same 
time intervals. The treatment can be continued or resumed if 
the Subject's clinical parameters indicate that poxvirus infec 
tion is present and can be maintained until the infection is no 
longer detected by these parameters and/or until the desired 
immunological response is achieved. 
0044) Ifex vivo methods are employed, cells or tissues can 
be removed and maintained outside the subject’s body 
according to standard protocols well known in the art. The 
polypeptides and/or biologically active fragments of this 
invention can be introduced into the cells via known mecha 
nisms for uptake of polypeptides into cells (e.g., phagocyto 
sis, pulsing onto class I MHC-expressing cells, liposomes, 
etc.). The cells can then beinfused (e.g., in a pharmaceutically 
acceptable carrier) or transplanted back into the Subject per 
standard methods for the cellor tissue type. Standard methods 
are known for transplantation or infusion of various cells into 
a Subject. 
0045. The pharmaceutical compositions of this invention 
include those Suitable for oral, rectal, topical, inhalation (e.g., 
via an aerosol) buccal (e.g., Sub-lingual), vaginal, parenteral 
(e.g., Subcutaneous, intramuscular, intradermal, intraarticu 
lar, intrapleural, intraperitoneal, intracerebral, intraarterial, or 
intravenous), topical (i.e., both skin and mucosal Surfaces, 
including airway Surfaces) and transdermal administration, 
although the most Suitable route in any given case will 
depend, as is well known in the art, on Such factors as the 
species, age, gender and overall condition of the Subject, the 
nature and severity of the condition being treated and/or on 
US 2012/O294.896 A1 
the nature of the particular composition (i.e., dosage, formu 
lation) that is being administered. 
0046 Pharmaceutical compositions suitable for oral 
administration can be presented in discrete units, such as 
capsules, cachets, lozenges, or tables, each containing a pre 
determined amount of the composition of this invention; as a 
powder or granules; as a solution or a Suspension in an aque 
ous or non-aqueous liquid; or as an oil-in-water or water-in 
oil emulsion. Oral delivery can be performed by complexing 
a composition of the present invention to a carrier capable of 
withstanding degradation by digestive enzymes in the gut of 
an animal. Examples of such carriers include plastic capsules 
ortablets, as known in the art. Such formulations are prepared 
by any suitable method of pharmacy, which includes the step 
of bringing into association the composition and a suitable 
carrier (which may contain one or more accessory ingredients 
as noted above). In general, the pharmaceutical composition 
according to embodiments of the present invention are pre 
pared by uniformly and intimately admixing the composition 
with a liquid or finely divided solid carrier, or both, and then, 
if necessary, shaping the resulting mixture. For example, a 
tablet can be prepared by compressing or molding a powder 
or granules containing the composition, optionally with one 
or more accessory ingredients. Compressed tablets are pre 
pared by compressing, in a suitable machine, the composition 
in a free-flowing form, such as a powder or granules option 
ally mixed with a binder, lubricant, inert diluent, and/or sur 
face active/dispersing agent(s). Molded tablets are made by 
molding, in a suitable machine, the powdered compound 
moistened with an inert liquid binder. 
0047 Pharmaceutical compositions suitable for buccal 
(Sub-lingual) administration include lozenges comprising the 
composition of this invention in a flavored base, usually 
Sucrose and acacia or tragacanth; and pastilles comprising the 
composition in an inert base Such as gelatin and glycerin or 
Sucrose and acacia. 
0048 Pharmaceutical compositions of this invention suit 
able for parenteral administration can comprise sterile aque 
ous and non-aqueous injection Solutions of the composition 
of this invention, which preparations are preferably isotonic 
with the blood of the intended recipient. These preparations 
can contain anti-oxidants, buffers, bacteriostats and solutes, 
which render the composition isotonic with the blood of the 
intended recipient. Aqueous and non-aqueous sterile Suspen 
sions, Solutions and emulsions can include Suspending agents 
and thickening agents. Examples of non-aqueous solvents are 
propylene glycol, polyethylene glycol, vegetable oils such as 
olive oil, and injectable organic esters such as ethyl oleate. 
Aqueous carriers include water, alcoholic/aqueous Solutions, 
emulsions or Suspensions, including saline and buffered 
media. Parenteral vehicles include sodium chloride solution, 
Ringer's dextrose, dextrose and sodium chloride, lactated 
Ringer's, or fixed oils. Intravenous vehicles include fluid and 
nutrient replenishers, electrolyte replenishers (such as those 
based on Ringer's dextrose), and the like. Preservatives and 
other additives may also be present such as, for example, 
antimicrobials, anti-oxidants, chelating agents, and inert 
gases and the like. 
0049. The compositions can be presented in unitvdose or 
multi-dose containers, for example, in sealed ampoules and 
vials, and can be stored in a freeze-dried (lyophilized) con 
dition requiring only the addition of the sterile liquid carrier, 
for example, saline or water-for-injection immediately prior 
tO use. 
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0050 Extemporaneous injection solutions and suspen 
sions can be prepared from sterile powders, granules and 
tablets of the kind previously described. For example, an 
injectable, stable, Sterile composition of this invention in a 
unit dosage form in a sealed container can be provided. The 
composition can be provided in the form of a lyophilizate, 
which can be reconstituted with a suitable pharmaceutically 
acceptable carrier to form a liquid composition Suitable for 
injection into a subject. The unit dosage form can be from 
about 1 ug to about 10 grams of the composition of this 
invention. When the composition is substantially water-in 
soluble, a sufficient amount of emulsifying agent, which is 
physiologically acceptable, can be included in Sufficient 
quantity to emulsify the composition in an aqueous carrier. 
One Such useful emulsifying agent is phosphatidylcholine. 
0051 Pharmaceutical compositions suitable for rectal 
administration are preferably presented as unit dose Supposi 
tories. These can be prepared by admixing the composition 
with one or more conventional Solid carriers, such as for 
example, cocoa butter and then shaping the resulting mixture. 
0.052 Pharmaceutical compositions of this invention suit 
able for topical application to the skin preferably take the 
form of an ointment, cream, lotion, paste, gel, spray, aerosol, 
or oil. Carriers that can be used include, but are not limited to, 
petroleum jelly, lanoline, polyethylene glycols, alcohols, 
transdermal enhancers, and combinations of two or more 
thereof. In some embodiments, for example, topical delivery 
can be performed by mixing a pharmaceutical composition of 
the present invention with a lipophilic reagent (e.g., DMSO) 
that is capable of passing into the skin. 
0053 Pharmaceutical compositions suitable for transder 
mal administration can be in the form of discrete patches 
adapted to remain in intimate contact with the epidermis of 
the Subject for a prolonged period of time. Compositions 
suitable for transdermal administration can also be delivered 
by iontophoresis (see, for example, Pharmaceutical Research 
3:318 (1986)) and typically take the form of an optionally 
buffered aqueous solution of the composition of this inven 
tion. Suitable formulations can comprise citrate or bis\tris 
buffer (pH 6) or ethanol/water and can contain from 0.1 to 
0.2M active ingredient. 
0054 The present invention further provides a medica 
ment and the preparation thereof for use in treating and/or 
preventing the disease and disorders described herein by 
employing the same steps as described in the methods dis 
closed herein. Also provided herein is a medicament and the 
preparation thereof for use in modulating (enhancing, treat 
ing or preventing a detrimental immune response, inhibiting, 
etc.) an immune response according to the steps of the meth 
ods described herein. It is further contemplated that the meth 
ods, compositions and medicaments of this invention can be 
used for veterinary application as well as in applications 
involving humans. 
0055. Furthermore, the nucleic acids and vectors of this 
invention can be administered orally, intranasally, parenter 
ally (e.g., intravenously), by intramuscular injection, by intra 
peritoneal injection, transdermally, extracorporeally, topi 
cally or the like. In the methods described herein which 
include the administration and uptake of exogenous DNA 
into the cells of a Subject (i.e., gene transduction or transfec 
tion), the nucleic acids of the present invention can be in the 
form of naked DNA or the nucleic acids can be in a vector for 
delivering the nucleic acids to the cells for expression of the 
polypeptides and/or fragments of this invention. The vector 
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can be a commercially available preparation or can be con 
structed in the laboratory according to methods well known in 
the art. 
0056 Delivery of the nucleic acid or vector to cells can be 
via a variety of mechanisms. As one example, delivery can be 
via a liposome, using commercially available liposome 
preparations such as LIPOFECTIN, LIPOFECTAMINE 
(GIBCO-BRL, Inc., Gaithersburg, Md.), SUPERFECT 
(Qiagen, Inc. Hilden, Germany) and TRANSFECTAM 
(Promega Biotec, Inc., Madison, Wis.), as well as other lipo 
Somes developed according to procedures standard in the art. 
In addition, the nucleic acid or vector of this invention can be 
delivered in vivo by electroporation, the technology for which 
is available from Genetronics, Inc. (San Diego, Calif.) as well 
as by means of a SONOPORATION machine (ImaRx Phar 
maceutical Corp., Tucson, Ariz.). 
0057. As one example, vector delivery can be via a viral 
system, Such as a retroviral vector system, which can package 
a recombinant retroviral genome. The recombinant retrovirus 
can then be used to infect and thereby deliver to the infected 
cells nucleic acid encoding the polypeptide and/or fragment 
of this invention. The exact method of introducing the exog 
enous nucleic acid into mammalian cells is, of course, not 
limited to the use of retroviral vectors. Other techniques are 
widely available for this procedure including the use of aden 
Oviral vectors, alphaviral vectors, adeno-associated viral 
(AAV) vectors, lentiviral vectors, pseudotyped retroviral vec 
tors and vaccinia viral vectors, as well as any other viral 
vectors now known or developed in the future. Physical trans 
duction techniques can also be used, such as liposome deliv 
ery and receptor-mediated and other endocytosis mecha 
nisms. This invention can be used in conjunction with any of 
these or other commonly used gene transfer methods. 
0058 As one example, the nucleic acid of this invention is 
delivered to the cells of a subject in a vaccinia virus vector, the 
dosage for administration of vaccinia virus to humans can 
typically range from about 10 to 10 pfu per injection, but in 
some embodiments, can be as high as 10'. 10' and/or 10' 
pful per injection. 
0059. As another example, if the nucleic acid of this inven 
tion is delivered to the cells of a subject in an adenovirus 
vector, the dosage for administration of adenovirus to humans 
can range from about 10 to 10 plaque forming units (pfu) 
per injection, but can be as high as 10'10", 10' and/or 10' 
pful per injection. 
0060. In some embodiments, a subject will receive a single 
injection of a viral vector comprising a nucleic acid of this 
invention. If additional injections are necessary, they can be 
repeated at daily/weekly/monthly intervals for an indefinite 
period and/or until the efficacy of the treatment has been 
established. As set forth herein, the efficacy of treatment can 
be determined by evaluating the symptoms and clinical 
parameters described herein and/or by detecting a desired 
immunological response. 
0061. The exact amount of the nucleic acid or vector 
required will vary from Subject to Subject, depending on the 
species, age, weight and general condition of the Subject, the 
particular nucleic acid or vector used, its mode of adminis 
tration and the like. Thus, it is not possible to specify an exact 
amount for every nucleic acid or vector. However, an appro 
priate amount can be determined by one of ordinary skill in 
the art using only routine experimentation given the teachings 
herein. 
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0062. The present invention further provides a method of 
diagnosing a poxvirus infection in a Subject, comprising: a) 
contacting a sample from the Subject with an antibody that 
specifically binds an A35R protein under conditions whereby 
an antigen/antibody complex can form; and b) detecting for 
mation of the antigen/antibody complex, thereby diagnosing 
poxvirus infection in a subject. 
0063 Also provided herein is a method of diagnosing 
poxvirus infection in a subject, comprising: a) contacting a 
sample from the subject with an A35R protein or antigenic 
fragment thereof under conditions whereby an antigen/anti 
body complex can form; and b) detecting formation of the 
antigen/antibody complex, thereby diagnosing poxvirus 
infection in a Subject. 
0064. In other embodiments, a method is provided of 
detecting poxvirus in a sample, comprising: a) contacting the 
sample with an antibody that specifically binds A35R protein 
under conditions whereby an antigen/antibody complex can 
form; and b) detecting formation of the antigen/antibody 
complex, thereby detecting poxvirus in the sample. 
0065. Further provided is a method of detecting an anti 
body to poxvirus in a sample, comprising: a) contacting the 
sample with an A35R protein or antigenic fragment thereof 
under conditions whereby an antigen/antibody complex can 
form; and b) detecting formation of the antigen/antibody 
complex, thereby detecting an antibody to poxvirus in the 
sample. 
0066. The present invention provides a method of detect 
ing a nucleic acid comprising a nucleotide sequence encoding 
A35R protein in a sample, comprising: a) contacting the 
sample with an oligonucleotide comprising a nucleotide 
sequence that is complementary to the nucleotide sequence 
encoding A35R protein, under conditions whereby nucleic 
acid hybridization can occur; and b) detecting nucleic acid 
hybridization, thereby detecting nucleic acid comprising the 
nucleotide sequence encoding A35R protein in the sample. 
0067. Additionally provided is a method of detecting 
nucleic acid comprising a nucleotide sequence encoding 
A35R protein in a sample, comprising: a) contacting the 
sample with a pair of oligonucleotide primers that are 
complementary to the nucleotide sequence encoding A35R 
protein, under conditions whereby nucleic acid amplification 
can occur; and b) detecting nucleic acid amplification, 
thereby detecting nucleic acid comprising the nucleotide 
sequence encoding A35R protein in the sample. 
0068 A sample of this invention can be any sample in 
which poxvirus proteins and/or nucleic acids can be present. 
For example, the sample can be a body fluid, cells or tissue, 
including but not limited to, blood, serum, plasma, saliva, 
sputum, broncheoalveolar lavage, urine, semen, joint fluid, 
cerebrospinal fluid and cells, fluids and/or tissue from all 
organs to which poxvirus antigens can disseminate including 
lung, liver, heart, brain, kidney, spleen, muscle, etc. A sample 
of this invention can also include a substance not obtained 
from the body of a subject of this invention. Examples of such 
a sample include but are not limited to, a water sample, a food 
or foodstuff sample, a plant or plant material sample, a Soil or 
dirt sample, an effluent sample, etc. 
0069. In further embodiments, the compositions of this 
invention can also be used to treat or prevent cancer in a 
Subject. Thus, in additional embodiments, the present inven 
tion provides a method of treating cancer in a Subject, com 
prising administering to the Subject a poxvirus engineered to 
lack A35R protein activity. A poxvirus employed in these 
methods would be a poxvirus that is specific for cancer cells. 
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0070. In other embodiments, the present invention pro 
vides a method of treating cancer in a subject, comprising 
administering to the Subject a poxvirus engineered to lack 
A35R protein activity and wherein the poxvirus can further 
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invention. In particular, the present invention provides an 
isolated nucleic acid comprising, consisting essentially of 
and/or consisting of the nucleotide sequence of Vaccinia virus 
Copenhagen strain (SEQID NO:1): 
atggacgcc.gc.gtttgtt attact coaatgggtgttgttgactataacagata cattgtatgatgatct cqatatttcaat catggactittataggacc 
ata cattataggtaacataaaaactgtccaaatagatgtacgggatataaaatatt ccgacatgcaaaaatgct actittagctataagggtaaaat 
agttcct caggattictaatgatttggctagattcaacatttatago atttgttgcc.gcatacagat caaaaaataccatcat catago atgcgacitat 
gatat catgttagatatagaagataaacat cagccatttitat ct attcc catctattgatgtttittaacgctacaat catagaag.cgtata acctgtata 
cagctggagattatcatctaat catcaatcc titcagataatctgaaaatgaaattgtcgtttaattct tcattctgcatat cagacggcaatggatgg 
attataattgatgggaaatgcaat agtaaattittittatca. 
comprise a) nucleic acid encoding a costimulatory molecule 
(e.g., B7.1, ICAM-1, LFA-3, etc., as known in the art); b) 
nucleic acid encoding a tumor antigen; and c) nucleic acid 
encoding an immunomodulatory protein or molecule. These 
nucleic acids can be present separately and/or in any combi 
nation in the poxvirus genome. 
0071. The present invention further provides composi 
tions. Thus, in one embodiment, provided herein is a compo 
sition comprising A35R protein and a pharmaceutically 
acceptable carrier. In other embodiments, a poxvirus engi 
neered to lack A35R activity is provided. Further provided is 
a composition comprising a poxvirus engineered to lack 
0074. Further provided herein is the nucleotide sequence 
of the A35R protein of all of the poxviruses identified in Table 
1 by virus name, gene name for the A35R ortholog, the 
GenBank(R) database accession number, the number of amino 
acids and the location of the start and stop sites of the open 
reading frame (ORF) for A35R. Each of these nucleotide 
sequences is incorporated by reference herein in their 
entirety. 
0075 Additionally provided is a nucleic acid comprising, 
consisting essentially of, and/or consisting of a nucleotide 
sequence that encodes an amino acid sequence comprising, 
consisting essentially of, and/or consisting of the amino acid 
sequence or a biologically active fragment of any of the 
following amino acid sequences: 




Variola virus strain Garcia A39R gene/protein: (SEQ ID NO : 3) : 
MDTTFWITPMGMLTITDTLYDDLDISIMDFIGPYIIGNIKTVOIDVRDIKYSDMOKCYFS, 
and 
Variola virus strain India A38R: (SEQ ID NO : 4) : 
MDTTFWITPMGMLTITDTLYDDLDISIMDFIGPYIIGNIKTVOIDVRDIKYSDMOKCYFS 
A35R activity and a pharmaceutically acceptable carrier. 
Also provided herein is an isolated nucleic acid encoding an 
A35R protein or active fragment thereof of a vaccinia virus or 
other poxvirus. Additionally provided herein is a composition 
comprising an isolated nucleic acid encoding an A35R pro 
tein or active fragment thereof of a vaccinia virus and a 
pharmaceutically acceptable carrier. In further embodiments, 
the present invention provides a composition comprising an 
antibody that specifically binds an A35R protein or active 
fragment thereof and a pharmaceutically acceptable carrier, 
as well as an antibody that specifically binds an A35R protein 
or active fragment thereof. 
0072. As indicated herein, the present invention provides 
biologically active fragments of the proteins of this invention, 
as well as antibodies that specifically bind the proteins and/or 
fragments of the proteins of this invention. 
0073. Further provided are isolated nucleic acids compris 
ing, consisting essentially of and/or consisting of nucleotide 
sequences that encode the proteins and fragments of this 
0076 Further provided herein is a nucleic acid that is the 
complement of each and any of the nucleic acids of this 
invention. 
0077. The present invention also provides an isolated 
A35R protein, which can be a protein having the amino acid 
sequence of SEQID NO:2. Also provided herein is the amino 
acid sequence for the A35R protein of the poxviruses identi 
fied in Table 1, as available in the GenBank(R) database. These 
amino acid sequences are incorporated by reference herein in 
their entirety. Specific examples of nucleotide sequences of 
poxviruses of this invention, such as Bovine popular stoma 
titis virus (SEQID NO:8), Camelpox virus (SEQ ID NO:9), 
Cowpox virus (SEQ ID NO:10), Deerpox virus (SEQ ID 
NO:11), Ectromelia virus (SEQ ID NO:12), Goatpox virus 
Pellor (SEQ ID NO:13), lumpy skin disease virus (SEQ ID 
NO:14), Molluscum contagiosum virus (SEQ ID NO:15), 
Monkeypox virus (SEQ ID NOS:16, 17 and 18), Myxoma 
virus (SEQ ID NO:19), Orf virus (SEQID NO:20), Rabbit 
pox virus (SEQ ID NO:21), Rabbit fibroma virus (SEQ ID 
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NO:22), sheeppox virus (SEQ ID NO:23), Swinepox virus 
(SEQID NO:24), Vaccinia virus (SEQID NOS:25, 26, 27, 28 
and 29), Yaba-like disease virus (SEQ ID NO:30) and Yaba 
like monkey tumor virus (SEQID NO:31) are provided in 
Table 2. Specific examples of amino acid sequences of pox 
viruses of the invention, such as Bovine popular stomatitis 
virus (SEQ ID NO:32), Deerpox virus (SEQ ID NO:33), 
lumpy skin disease virus (SEQID NO:34), Molluscum con 
tagiosum virus (SEQ ID NO:35), Myxoma virus (SEQ ID 
NO:36), Orf virus (SEQID NO:37), sheeppox virus (SEQID 
NO:38), Swinepox virus (SEQ ID NO:39), Vaccinia virus 
(SEQ ID NO:40), Variola virus (SEQ ID NO:41), Yaba-like 
disease virus (SEQID NO:42) and Yaba-like monkey tumor 
virus (SEQID NO:43) are provided in Table 3. 
0078. Also provided herein are probes and primers for the 
detection of the nucleic acids of this invention and Such prim 
ers and/or probes can be used alone and/or in any combina 
tion. Probes and primers of this invention can be prepared 
according to art known methods for identifying primer pairs 
and probes using art-known procedures and/or commercially 
available software for identifying regions that are optimal for 
priming and probing protocols. As would be known to one of 
ordinary skill in the art, any part of the A35R nucleotide 
sequence of this invention (or its complement) could be used 
as a primer and/or probe. A nonlimiting example of a primer 
pair is: 5' atggacgccg.cgtttgttatta 3 (SEQ ID NO:5) and 5' 
tgataaaaaattactatt 3 (SEQID NO:6), which could be used to 
amplify an A35R sequence by PCR. An example of a probe to 
detect A35R nucleic acid could be 5' tgataaaaaattactattgc 3' 
(SEQ ID NO:7). 
0079. In certain embodiments, the fragments and/or 
polypeptides of this invention can be fused with a “carrier' 
protein or peptide to produce a fusion protein. Such fusion 
can be carried out, for example, by linking a nucleic acid of 
this invention in frame with a nucleic acid encoding a carrier 
protein or fragment thereof of this invention and expressing 
the linked nucleotide sequence to produce the fusion protein. 
For example, the carrier protein or peptide can be fused to a 
polypeptide and/or fragment of this invention to increase the 
stability thereof (e.g., decrease the turnover rate) in the cell 
and/or subject. Exemplary carrier proteins include, but are not 
limited to, glutathione-S-transferase or maltose-binding pro 
tein. The carrier protein or peptide can alternatively be a 
reporter protein. For example, the fusion protein can com 
prise a polypeptide and/or fragment of this invention and a 
reporter protein or peptide (e.g., green fluorescence protein 
(GFP), B-glucoronidase, B-galactosidase, luciferase, and the 
like) for easy detection of transformed cells and transgene 
expression. Any suitable carrier protein and/or nucleic acid 
encoding the carrier protein, as is well known in the art can be 
used to produce a fusion protein of this invention. 
0080 A variety of protocols for detecting the presence of 
and/or measuring the amount of polypeptides, fragments and/ 
or peptides of this invention in a sample, using polyclonal 
and/or monoclonal antibodies specific for the polypeptide, 
fragment and/or peptide are known in the art. Examples of 
Such protocols include, but are not limited to, enzyme immu 
noassays (EIA), agglutination assays, immunoblots (Western 
blot, dot/slot blot, etc.), radioimmunoassays (RIA), immun 
odiffusion assays, chemiluminescence assays, antibody 
library Screens, expression arrays, enzyme-linked immun 
osorbent assays (ELISA), radioimmunoassays (RIA), immu 
noprecipitation, Western blotting, competitive binding 
assays, immunofluorescence, immunohistochemical staining 
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precipitation/flocculation assays and fluorescence-activated 
cell sorting (FACS). These and other assays are described, 
among other places, in Hampton et al. (Serological Methods, 
a Laboratory Manual, APS Press, St Paul, Minn. (1990)) and 
Maddox et al. (J Exp. Med. 158:1211-1216 (1993)). 
I0081 Furthermore, a number of assays for identification, 
detection and/or amplification of nucleic acid sequences are 
well known in the art. For example, various protocols can be 
employed in the methods of this invention to amplify nucleic 
acid. As used herein, the term "oligonucleotide-directed 
amplification procedure” refers to template-dependent pro 
cesses that result in an increase in the concentration of a 
specific nucleic acid molecule relative to its initial concentra 
tion, or in an increase in the concentration of a detectable 
signal. Such as amplification. As used herein, the term "oli 
gonucleotide directed mutagenesis procedure' is intended to 
refer to a process that involves the template-dependent exten 
sion of a primer molecule. The term “template dependent 
process' refers to nucleic acid synthesis of a RNA or a DNA 
molecule wherein the sequence of the newly synthesized 
strand of nucleic acid is dictated by the well-known rules of 
complementary base pairing. Typically, vector mediated 
methodologies involve the introduction of the nucleic acid 
fragment into a DNA or RNA vector, the clonal amplification 
of the vector, and the recovery of the amplified nucleic acid 
fragment. Examples of Such methodologies are provided in 
U.S. Pat. No. 4.237,224 (incorporated herein by reference in 
its entirety). Nucleic acids, used as a template for amplifica 
tion methods can be isolated from cells according to standard 
methodologies (Sambrook et al., 1989). The nucleic acid can 
be genomic DNA or fractionated or whole cell RNA. Where 
RNA is used, it may be desired to convert the RNA to a 
complementary DNA. In one embodiment, the RNA can be 
whole cell RNA and is used directly as the template for 
amplification. 
I0082 Pairs of primers that selectively hybridize to nucleic 
acids corresponding to the A35R gene or coding sequence are 
contacted with the nucleic acid under conditions that permit 
selective hybridization. The term “primeras defined herein, 
is meant to encompass any nucleic acid that is capable of 
priming the synthesis of a nascent nucleic acid in a template 
dependent process. Typically, primers are oligonucleotides 
from ten to twenty bases in length, but shorter (e.g., 6, 7, 8, or 
9 bases) or longer (e.g., 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 
35, 40, 45,50 bases) sequences can be employed. Primers can 
in double-stranded or single-stranded form, although the 
single-stranded form is commonly used. 
I0083. Once hybridized, the nucleic acid: primer hybrid 
ization complex is contacted with one or more enzymes that 
facilitate template-dependent nucleic acid synthesis. Mul 
tiple rounds of amplification, also referred to as “cycles.” are 
conducted until a sufficient amount of amplification product 
is produced. 
I0084. Next, the amplification product is detected. In some 
embodiments, the detection can be performed by visual 
means. Alternatively, the detection can involve indirect iden 
tification of the product via chemiluminescence, radioactive 
Scintigraphy of incorporated radiolabel or fluorescence or 
chemiluminescence label or even via a system using electrical 
or thermal impulse signals (e.g., Affymax technology). 
I0085. A number of template dependent processes are 
available to amplify the sequences present in a given template 
sample. One of the best-known amplification methods is the 
polymerase chain reaction (referred to as PCR), which is 
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described in detail in U.S. Pat. Nos. 4,683,195, 4,683.202 and 
4,800,159, each incorporated herein by reference in its 
entirety. 
I0086 Briefly, in PCR, two primer sequences are prepared 
that are complementary to regions on opposite complemen 
tary strands of the target sequence. An excess of deoxynucleo 
side triphosphates is added to a reaction mixture along with a 
DNA polymerase, e.g., a Taq polymerase. If the particular 
target sequence is present in a sample, the primers will bind to 
the target sequence and the polymerase will cause the primers 
to be extended along the sequence by adding on nucleotides. 
By raising and lowering the temperature of the reaction mix 
ture, the extended primers will dissociate from the target 
sequence to form reaction products, excess primers will bind 
to the target sequence and to the reaction products and the 
process is repeated. 
0087. A reverse transcriptase PCR amplification proce 
dure can be performed in order to quantify the amount of 
mRNA amplified. Methods of reverse transcribing RNA into 
cDNA are well known in the art (e.g., Sambrook et al., 1989). 
Alternative methods for reverse transcription employ thermo 
stable, RNA-dependent DNA polymerases. These methods 
are described, for example, in PCT Publication No. WO 
90/07641, filed Dec. 21, 1990, incorporated herein by refer 
ence in its entirety. Polymerase chain reaction methodologies 
are well known in the art. 
0088 Another method for nucleic acid amplification is the 
ligase chain reaction (“LCR), disclosed in Eur. Pat. Appl. 
No. 320308, incorporated herein by reference in its entirety. 
In LCR, two complementary probe pairs are prepared and in 
the presence of the target sequence, each pair will bind to 
opposite complementary Strands of the target such that they 
abut. In the presence of a ligase, the two probe pairs will link 
to form a single unit. By temperature cycling, as in PCR, 
bound ligated units dissociate from the target and then serve 
as “target sequences' for ligation of excess probe pairs. U.S. 
Pat. No. 4,883,750 (incorporated by reference herein in its 
entirety) describes a method similar to LCR for binding probe 
pairs to a target sequence. 
I0089 Qbeta replicase (QPR), described in PCT Applica 
tion No. PCT/US87/00880, (incorporated herein by refer 
ence), can also be used as an amplification method in the 
present invention. In this method, a replicative sequence of 
RNA that has a region complementary to that of a target is 
added to a sample in the presence of an RNA polymerase. The 
polymerase will copy the replicative sequence that can then 
be detected. 
0090. An isothermal amplification method, in which 
restriction endonucleases and ligases are used to achieve the 
amplification of target molecules that contain nucleotide 5'- 
alpha-thiotriphosphates in one strand of a restriction site 
may also be useful in the amplification of nucleic acids in the 
present invention. 
0091 Strand Displacement Amplification (SDA), 
described in U.S. Pat. Nos. 5,455,166, 5,648,211, 5,712,124 
and 5,744,311, each incorporated herein by reference, is 
another method of carrying out isothermal amplification of 
nucleic acids which involves multiple rounds of strand dis 
placement and synthesis, i.e., nick translation. A similar 
method, called Repair Chain Reaction (RCR), involves 
annealing several probes throughout a region targeted for 
amplification, followed by a repair reaction in which only two 
of the four bases are present. 
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0092. The other two bases can be added as biotinylated 
derivatives for easy detection. A similar approach is used in 
SDA. Target specific sequences can also be detected using a 
cyclic probe reaction (CPR). In CPR, a probehaving 3' and 5' 
sequences of non-specific DNA and a middle sequence of 
specific RNA is hybridized to DNA that is present in a sample. 
Upon hybridization, the reaction is treated with RNase H, and 
the products of the probe identified as distinctive products 
that are released after digestion. The original template is 
annealed to another cycling probe and the reaction is 
repeated. 
0093 Still another amplification method, as described in 
Intl. Pat. Appl. No. PCT/US89/01025, which is incorporated 
herein by reference in its entirety, may be used in accordance 
with the present invention. In one embodiment, “modified 
primers are used in a PCR-like, template- and enzyme-depen 
dent synthesis. The primers may be modified by labeling with 
a capture moiety (e.g., biotin) and/or a detectable moiety 
(e.g., enzyme). In another embodiment, an excess of labeled 
probes is added to a sample. In the presence of the target 
sequence, the probe binds and is cleaved catalytically. After 
cleavage, the target sequence is released intact, available to be 
bound by excess probe. Cleavage of the labeled probe signals 
the presence of the target sequence. 
0094. Other nucleic acid amplification procedures include 
transcription-based amplification systems (TAS), including 
nucleic acid sequence based amplification (NASBA) and 3SR 
(PCT Publication No. WO 88/10315, incorporated herein by 
reference). In NASBA, the nucleic acids can be prepared for 
amplification by standard phenol/chloroform extraction, heat 
denaturation of a clinical sample, treatment with lysis buffer 
and minispin columns for isolation of DNA and RNA or 
guanidinium chloride extraction of RNA. These amplifica 
tion techniques involve annealing a primer that has target 
specific sequences. Following polymerization, DNA/RNA 
hybrids are digested with RNase H while double stranded 
DNA molecules are heat denatured again. In either case the 
single stranded DNA is made fully double stranded by addi 
tion of second target specific primer, followed by polymer 
ization. The double-stranded DNA molecules are then multi 
ply transcribed by an RNA polymerase such as T7, T3 or SP6. 
In an isothermal cyclic reaction, the RNAs are reverse tran 
scribed into single stranded DNA, which is then converted to 
double-stranded DNA, and then transcribed once again with 
an RNA polymerase such as T7, T3 or SP6. The resulting 
products, whether truncated or complete, indicate target spe 
cific sequences. 
(0095 Eur. Pat. Appl. No. 329822 (incorporated herein by 
reference in its entirety) discloses a nucleic acid amplification 
process involving cyclically synthesizing single stranded 
RNA (ssERNA), ssDNA, and double-stranded DNA (dsDNA), 
which can be used in accordance with the present invention. 
The ssRNA is a template for a first primer oligonucleotide, 
which is elongated by reverse transcriptase (RNA-dependent 
DNA polymerase). The RNA is then removed from the result 
ing DNA:RNA duplex by the action of ribonuclease H 
(RNase H, an RNase specific for RNA in duplex with either 
DNA or RNA). 
0096. The resultant ssDNA is a template for a second 
primer, which also includes the sequences of an RNA poly 
merase promoter (exemplified by T7 RNA polymerase) 5’ to 
its homology to the template. This primer is then extended by 
DNA polymerase (exemplified by the large Klenow fragment 
of E. coli DNA polymerase I), resulting in a double-stranded 
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DNA (dsDNA) molecule, having a sequence identical to that 
of the original RNA between the primers and having addi 
tionally, at one end, a promoter sequence. This promoter 
sequence can be used by the appropriate RNA polymerase to 
make many RNA copies of the DNA. These copies can then 
re-enter the cycle, leading to very swift amplification. With 
proper choice of enzymes, this amplification can be done 
isothermally without addition of enzymes at each cycle. 
Because of the cyclical nature of this process, the starting 
sequence can be chosen to be in the form of either DNA or 
RNA. 
0097. PCT Application WO 89/06700 (incorporated 
herein by reference in its entirety) discloses a nucleic acid 
sequence amplification scheme based on the hybridization of 
a promoter/primer sequence to a target single-stranded DNA 
(ssDNA), followed by transcription of many RNA copies of 
the sequence. This scheme is not cyclic, i.e., new templates 
are not produced from the resultant RNA transcripts. Other 
amplification methods include “RACE and “one-sided 
PCR' (Frohman, 1990, incorporated by reference herein). 
0098 Methods based on ligation of two (or more) oligo 
nucleotides in the presence of nucleic acid having the 
sequence of the resulting “di-oligonucleotide, thereby 
amplifying the dioligonucleotide, can also be used in the 
amplification step of the present invention. 
0099. Following any amplification, it is desirable to sepa 
rate the amplification product from the template and the 
excess primer for the purpose of determining whether specific 
amplification has occurred. In one embodiment, amplifica 
tion products can be separated by agarose, agarose-acryla 
mide or polyacrylamide gel electrophoresis using standard 
methods (e.g., Sambrook et al., 1989). 
0100 Alternatively, chromatographic techniques can be 
used to effect separation. There are many kinds of chroma 
tography that can be used in the present invention: Such as, for 
example, adsorption, partition, ion exchange and molecular 
sieve, as well as many specialized techniques for using them, 
including column, paper, thin-layer and gas chromatography. 
0101 Amplification products must be visualized in order 
to confirm amplification of the target sequences. One typical 
visualization method involves staining of a gel with ethidium 
bromide and visualization under UV light. Alternatively, if 
the amplification products are integrally labeled with radio 
or fluorometrically-labeled nucleotides, the amplification 
products can then be exposed to X-ray film or visualized under 
the appropriate stimulating spectra, following separation. 
0102. In some embodiments, visualization is achieved 
indirectly. Following separation of amplification products, a 
labeled, nucleic acid probe is brought into contact with the 
amplified target sequence. The probe preferably is conjugated 
to a chromophore but may be radiolabeled. In another 
embodiment, the probe is conjugated to a binding partner, 
such as an antibody or biotin, and the other member of the 
binding pair carries a detectable moiety. 
0103) In other embodiments, detection can be by Southern 
blotting and hybridization with a labeled probe. The tech 
niques involved in Southern blotting are well known to those 
of skill in the art and can be found in many standardbooks on 
molecular protocols (e.g., Sambrook et al., 1989). Briefly, 
amplification products are separated by gel electrophoresis. 
The gel is then contacted with a membrane. Such as nitrocel 
lulose, permitting transfer of the nucleic acid and noncovalent 
binding. Subsequently, the membrane is incubated with a 
chromophore-conjugated probe that is capable of hybridizing 
Nov. 22, 2012 
with a target amplification product. Detection is by exposure 
of the membrane to X-ray film or ion-emitting detection 
devices. One example of the foregoing is described in U.S. 
Pat. No. 5.279,721, incorporated by reference herein, which 
discloses an apparatus and method for the automated electro 
phoresis and transfer of nucleic acids. The apparatus permits 
electrophoresis and blotting without external manipulation of 
the gel. 
0104. Additionally, a wide variety of labeling and conju 
gation techniques are known in the art that are used in various 
nucleic acid detection and amplification assays. Methods for 
producing labeled hybridization probes and/or PCR or other 
ligation primers for detecting and/or amplifying nucleic acid 
sequences can include, for example, oligolabeling, nick trans 
lation and end-labeling, as well as other well known methods. 
Alternatively, nucleic acid sequences encoding the polypep 
tides of this invention, and/or any functional fragment 
thereof, can be cloned into a plasmid or vector for detection 
and amplification. Such plasmids and vectors are well known 
in the art and are commercially available. It is also contem 
plated that the methods of this invention can be conducted 
using a variety of commercially available kits (e.g., Pharma 
cia & Upjohn; Promega; U.S. Biochemical Corp.). Suitable 
reporter molecules or labels, which can be used for ease of 
detection, include, for example, radionuclides, enzymes, 
fluorescence agents, chemiluminescence agents and chro 
mogenic agents, as well as Substrates, cofactors, inhibitors, 
magnetic particles and the like as are well known in the art. 
01.05 The present invention further includes isolated 
polypeptides, peptides, proteins, fragments, domains and/or 
nucleic acid molecules that are Substantially equivalent to 
those described for this invention. As used herein, “substan 
tially equivalent can refer both to nucleic acid and amino 
acid sequences, for example a mutant sequence, that varies 
from a reference sequence by one or more Substitutions, 
deletions, or additions, the net effect of which does not result 
in an undesirable adverse functional dissimilarity between 
reference and Subject sequences. In some embodiments, this 
invention can include Substantially equivalent sequences that 
have an adverse functional dissimilarity. For purposes of the 
present invention, sequences having equivalent biological 
activity and equivalent expression characteristics are consid 
ered Substantially equivalent. 
0106 The invention further provides homologs, as well as 
methods of obtaining homologs, of the polypeptides and/or 
fragments of this invention from other poxviruses. As used 
herein, an amino acid sequence or protein is defined as a 
homolog of a polypeptide or fragment of the present inven 
tion if it shares significant homology to one of the polypep 
tides and/or fragments of the present invention. Significant 
homology means at least 30%, 40%, 50%, 60%. 65%, 75%, 
80%, 85%, 90%. 95%, 98% and/or 100% homology with 
another amino acid sequence. Specifically, by using the 
nucleic acids disclosed herein as a probe or as primers, and 
techniques such as PCR amplification and colony/plaque 
hybridization, one skilled in the art can identify homologs of 
the polypeptides and/or fragments of this invention in any 
mammalian-tropic poxvirus 
0107. It is further contemplated that the present invention 
provides kits for detection of the polypeptides and/or frag 
ments and/or antibodies of this invention in a sample. In one 
embodiment, the kit can comprise one or more antibodies of 
this invention, along with suitable buffers, wash solutions 
and/or other reagents for the detection of antibody/antigen 
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complex formation. In an alternative embodiment, a kit of this 
invention can comprise a polypeptide, an antigenic peptide of 
the polypeptide of this invention, a fragment of this invention 
and/or an antigenic peptide of a fragment of this invention, 
along with suitable buffers, wash solutions and/or other 
reagents for the detection of antibody/antigen complex for 
mation. 
0108. The present invention further provides a kit for the 
detection of nucleic acid encoding the polypeptides and/or 
fragments of this invention. For example, in one embodiment, 
the kit can comprise one or more nucleic acids of this inven 
tion, along with suitable buffers, wash solutions and/or other 
reagents for the detection of hybridization complex formation 
and/or amplification product formation. 
0109. It would be well understood by one of ordinary skill 
in the art that the kits of this invention can comprise one or 
more containers and/or receptacles to hold the reagents (e.g., 
antibodies, antigens, nucleic acids) of the kit, along with 
appropriate buffers and/or wash solutions and directions for 
using the kit, as would be well known in the art. Such kits can 
further comprise adjuvants and/or other immunostimulatory 
or immunomodulating agents, as are well known in the art. 
0110. In further embodiments, the nucleic acids encoding 
the polypeptides and/or fragments of this invention can be 
part of a recombinant nucleic acid construct comprising any 
combination of restriction sites and/or functional elements as 
are well known in the art that facilitate molecular cloning and 
other recombinant DNA manipulations. Thus, the present 
invention further provides a recombinant nucleic acid con 
struct comprising a nucleic acid encoding a polypeptide and/ 
or biologically active fragment of this invention. 
0111. The present invention further provides a vector 
comprising a nucleic acid encoding a polypeptide and/or 
fragment of this invention. The vector can be an expression 
vector which contains all of the genetic components required 
for expression of the nucleic acid in cells into which the vector 
has been introduced, as are well known in the art. The expres 
sion vector can be a commercial expression vector or it can be 
constructed in the laboratory according to standard molecular 
biology protocols. The expression vector can comprise viral 
nucleic acid including, but not limited to, poxvirus, Vaccinia 
virus, adenovirus, retrovirus and/or adeno-associated virus 
nucleic acid. The nucleic acid or vector of this invention can 
also be in a liposome or a delivery vehicle, which can be taken 
up by a cell via receptor-mediated or other type of endocyto 
sis. 
0112. The nucleic acid of this invention can be in a cell, 
which can be a cell expressing the nucleic acid whereby a 
polypeptide and/or biologically active fragment of this inven 
tion is produced in the cell. In addition, the vector of this 
invention can be in a cell, which can be a cell expressing the 
nucleic acid of the vector whereby a polypeptide and/or bio 
logically active fragment of this invention is produced in the 
cell. It is also contemplated that the nucleic acids and/or 
vectors of this invention can be present in a host animal (e.g., 
a transgenic animal), which expresses the nucleic acids of this 
invention and produces the polypeptides and/or fragments of 
this invention. 
0113. The nucleic acid encoding the polypeptide and/or 
fragment of this invention can be any nucleic acid that func 
tionally encodes the polypeptides and/or fragments of this 
invention. To functionally encode the polypeptides and/or 
fragments (i.e., allow the nucleic acids to be expressed), the 
nucleic acid of this invention can include, for example, 
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expression control sequences, such as an origin of replication, 
a promoter, an enhancer and necessary information process 
ing sites, such as ribosome binding sites, RNA splice sites, 
polyadenylation sites and transcriptional terminator 
Sequences. 
0114 Nonlimiting examples of expression control 
sequences that can be present in a nucleic acid of this inven 
tion include promoters derived from metallothionine genes, 
actin genes, immunoglobulin genes, CMV, SV40, adenovi 
rus, bovine papilloma virus, etc. A nucleic acid encoding a 
selected polypeptide and/or fragment can readily be deter 
mined based upon the genetic code for the amino acid 
sequence of the selected polypeptide and/or fragment and 
many nucleic acids will encode any selected polypeptide 
and/or fragment. Modifications in the nucleic acid sequence 
encoding the polypeptide and/or fragment are also contem 
plated. Modifications that can be useful are modifications to 
the sequences controlling expression of the polypeptide and/ 
or fragment to make production of the polypeptide and/or 
fragment inducible or repressible as controlled by the appro 
priate inducer or repressor. Such methods are standard in the 
art. The nucleic acid of this invention can be generated by 
means standard in the art, Such as by recombinant nucleic acid 
techniques and/or by synthetic nucleic acid synthesis or in 
vitro enzymatic synthesis. 
0115 The nucleic acids and/or vectors of this invention 
can be transferred into a host cell (e.g., a prokaryotic or 
eukaryotic cell) by well-known methods, which vary depend 
ing on the type of cell host. For example, calcium chloride 
transfection is commonly used for prokaryotic cells, whereas 
calcium phosphate treatment, transduction and/or electropo 
ration can be used for other cell hosts. 
0116. The present invention also provides various screen 
ing assays to identify Substances that either enhance or inhibit 
the activity of A35R, either at the protein or nucleic acid level. 
0117. In one embodiment, provided herein is a method of 
identifying a substance having the ability to inhibit or 
enhance the binding activity of a polypeptide and/or biologi 
cally active fragment of this invention comprising contacting 
the substance with the A35R protein or a biologically active 
fragment thereof under conditions whereby binding can 
occur and detecting a decrease or increase in the amount of 
binding in the presence of the Substance as compared to a 
control amount of binding in the absence of the Substance, 
thereby identifying a substancehaving the ability to inhibitor 
enhance the binding activity of the A35R protein. 
0118. Inhibition or enhancement of binding activity can be 
detected by any of a variety of art-recognized methods for 
evaluating binding activity. As one example, the Substance to 
be tested and the A35R polypeptide and/or fragment can be 
contacted in the presence of target cells or a target Substrate 
known to bind the A35R polypeptide or fragment. The 
amount of binding of polypeptide or fragment to the cells or 
the Substrate in the presence of the Substance and the amount 
of binding of polypeptide or fragment to the cells or the 
substrate in the absence of the substance is determined and a 
decrease or increase in the amount of binding in the presence 
of the substance identifies the substance as having the ability 
to inhibit or enhance binding. Nonlimiting examples of bind 
ing targets for A35R protein include antibodies, antibody 
fragments, ligands, cellular proteins, viral proteins, Small 
molecules and/or drugs that specifically bind A35R protein or 
an active fragment thereof. 
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0119. In some embodiments, binding of the A35R 
polypeptide and/or fragment to target cells or a target Sub 
strate can be measured by attaching a detectable moiety to the 
polypeptide or fragment (e.g., a fluorescence moiety, his 
tochemically detectable moiety, radioactive moiety, etc.). The 
amount of detectable moiety can be measured in the presence 
and absence of the Substance to be tested and the amounts can 
be compared to determine inhibition or enhancement. 
0120 In addition, the present invention provides a method 
of identifying a substance having the ability to inhibit or 
enhance the immunomodulating activity of an A35R 
polypeptide and/or a biologically active fragment of this 
invention, comprising contacting the Substance with the 
A35R polypeptide of this invention and/or a biologically 
active fragment thereof under conditions whereby immuno 
modulating activity can occur and detecting a decrease or 
increase in the amount of immunomodulating activity in the 
presence of the Substance as compared to a control amount of 
immunomodulating activity in the absence of the Substance, 
thereby identifying a substancehaving the ability to inhibitor 
enhance the immunomodulating activity of the A35R protein. 
0121 Inhibition or enhancement of the immunomodulat 
ing activity of the A35R protein can be detected by any of a 
variety of art-recognized methods for evaluating immuno 
modulating activity, including the assays for nitric oxide pro 
duction and interleukin 2 (IL-2) secretion as described in the 
Examples section herein. 
0122 Further provided is a method of identifying a sub 
stance having the ability to enhance or inhibit the immuno 
genic activity of the A35R protein of this invention and/or a 
biologically active fragment thereof, comprising contacting 
the substance with the A35R protein or an immunogenic 
fragment thereof under conditions whereby a measurable 
immune response can be elicited and detecting an increase or 
decrease in the amount of immune response in the presence of 
the Substance, as compared to a control amount of immune 
response in the absence of the Substance, thereby identifying 
a Substance having the ability to enhance or inhibit immuno 
genic activity of the A35R protein. Assays to detect and 
measure immune responses are well known in the art and can 
be employed to detect either humoral or cellular immune 
responses. 
0123. It is also contemplated that the present invention 
includes methods of screening poxviruses for mutants defec 
tive in one or more of the biological activities of the A35R 
protein, for use, for example, in a vaccine preparation. Such 
mutants can be identified as having a defect in any of the 
biological activities of the A35R protein according to the 
protocols described herein and as are known in the art. Such 
mutants can be further tested for being attenuated in the 
ability to produce a clinical infection in a Subject (i.e., for 
virulence potential) and then further evaluated for use as a 
vaccine according to known protocols. 
0.124 For example, in one embodiment, poxviruses con 
taining a mutation in the A35R coding sequence or lacking the 
A35R coding sequence) can be generated through Such art 
known techniques as gene disruption and their virulence 
potential determined by challenge Studies in animals and by 
assessments of immunomodulating activity as described 
herein. In addition, complementation studies can be per 
formed to restore the defective activity of the A35R protein, in 
order to characterize the mutant. 
DEFINITIONS 
0125. As used herein, “a” or “an or “the can mean one or 
more than one. For example, “a” cell can mean one cell or a 
plurality of cells. 
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0.126 Also as used herein, “and/or refers to and encom 
passes any and all possible combinations of one or more of the 
associated listed items, as well as the lack of combinations 
when interpreted in the alternative (“or). 
0127. Furthermore, the term “about,” as used herein when 
referring to a measurable value Such as an amount of a com 
pound or agent of this invention, dose, time, temperature, and 
the like, is meant to encompass variations of +20%, +10%, 
+5%, +1%, +0.5%, or even +0.1% of the specified amount. 
I0128. A poxvirus of this invention includes but is not 
limited to vaccinia virus, molluscum contagiosum, camelpox 
virus, cowpox virus, ectromelia (mousepox) virus, rabbitpox 
virus, monkeypox virus, raccoonpox virus, taterapox virus, 
buffalopox virus variola major virus, variola minor virus, 
lumpy skin disease virus, Swinepox virus, Yaba virus, sheep 
pox virus, myxoma virus Volepox virus and any other poxvi 
rus that has an A35R protein, either now known or later 
identified. Additional poxviruses are listed in Table 1. 
I0129. The A35R gene and A35R protein of this invention 
is an A35R gene or A35R protein or its ortholog from a 
poxvirus of this invention. The A35R gene encodes a 176 
amino acid protein in VV Copenhagen Strain, modified vac 
cinia Ankara strain and Tian Tan Strain (GenBank 
AF095689). The VV-A35R orthologs are conserved in all 
poxviruses with a mammalian host range, ranging in size 
from 176 to 192 amino acids in all sequenced viruses, except 
for a large ortholog of 233 amino acids in molluscum conta 
giosum virus. The gene is fragmented into 60 amino acid and 
50 amino acid open reading frames (ORFs) in variola virus 
sequences (India, Bangladesh and Garcia). 
0.130. As used herein, “modulate.” “modulates' or “modu 
lation” refers to enhancement (e.g., an increase) or inhibition 
(e.g., diminished, reduced or Suppressed) of the specified 
activity. 
0131 The term "enhancement,” “enhance.” “enhances.” 
or 'enhancing refers to an increase in the specified parameter 
(e.g., at least about a 1.1-fold, 1.25-fold, 1.5-fold, 2-fold, 
3-fold, 4-fold, 5-fold, 6-fold, 8-fold, 10-fold, twelve-fold, or 
even fifteen-fold or more increase) and/or an increase in the 
specified activity of at least about 5%, 10%, 25%, 35%, 40%, 
50%, 60%, 75%, 80%, 90%, 95%, 97%, 98%, 99% or 100%. 
(0132) The term “inhibit,” “diminish.” “reduce” or “sup 
press' refers to a decrease in the specified parameter (e.g., at 
least about a 1.1-fold, 1.25-fold, 1.5-fold, 2-fold, 3-fold, 
4-fold, 5-fold, 6-fold, 8-fold, 10-fold, twelve-fold, or even 
fifteen-fold or more increase) and/or a decrease or reduction 
in the specified activity of at least about 5%, 10%, 25%, 35%, 
40%, 50%, 60%, 75%, 80%, 90%, 95%, 97%, 98%, 99% or 
100%. In particular embodiments, the inhibition or reduction 
results in little or essentially no detectible activity (at most, an 
insignificant amount, e.g., less than about 10% or about 5%). 
0.133 As used herein, the transitional phrase “consisting 
essentially of means that the scope of a claim is to be inter 
preted to encompass the specified materials or steps recited in 
the claim, “and those that do not materially affect the basic 
and novel characteristic(s) of the claimed invention. See. In 
re. Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 
1976) (emphasis in the original); see also MPEPS2111.03. 
Thus, the term “consisting essentially of when used in a 
claim of this invention is not intended to be interpreted to be 
equivalent to "comprising.” 
0.134 “Isolated” as used herein means the nucleic acid or 
protein or protein fragment of this invention is sufficiently 
free of contaminants or cell components with which nucleic 
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acids or proteins normally occur. “Isolated” does not mean 
that the preparation is technically pure (homogeneous), but it 
is sufficiently pure to provide the nucleic acid or protein or 
protein fragment in a form in which it can be used therapeu 
tically. 
0135 “Epitope' or “antigenic epitope' or “antigenic pep 
tide' as used herein means a specific amino acid sequence 
which, when present in the proper conformation, provides a 
reactive site for an antibody or T cell receptor. The identifi 
cation of epitopes on antigens can be carried out by immu 
nology protocols that are well known in the art. Typically, an 
epitope or antigenic peptide can be 4, 5, 6, 7, 8, 9, 10, 12, 14, 
16, 18, 20, 25, 30, 35, 40, 45 or 50 amino acids in length. 
0136. As used herein, the term “polypeptide' or “protein’ 
is used to describe a chain of amino acids that correspond to 
those encoded by a nucleic acid. A polypeptide of this inven 
tion can be a peptide, which usually describes a chain of 
amino acids of from two to about 30 amino acids. The term 
polypeptide as used herein also describes a chain of amino 
acids having more than 30 amino acids and can be a fragment 
or domain of a protein or a full length protein. Furthermore, as 
used herein, the term polypeptide can refer to a linear chain of 
amino acids or it can refer to a chain of amino acids that has 
been processed and folded into a functional protein. It is 
understood, however, that 30 is an arbitrary number with 
regard to distinguishing peptides and polypeptides and the 
terms can be used interchangeably for a chain of amino acids. 
The polypeptides of the present invention are obtained by 
isolation and purification of the polypeptides from cells 
where they are produced naturally, by enzymatic (e.g., pro 
teolytic) cleavage, and/or recombinantly by expression of 
nucleic acid encoding the polypeptides or fragments of this 
invention. The polypeptides and/or fragments of this inven 
tion can also be obtained by chemical synthesis or other 
known protocols for producing polypeptides and fragments. 
0.137 The amino acid sequences disclosed herein are pre 
sented in the amino to carboxy direction, from left to right. 
Nucleotide sequences are presented herein in the 5' to 3' 
direction, from left to right. It is intended that the nucleic 
acids of this invention can be either single or double stranded 
(i.e., including the complementary nucleic acid). A nucleic 
acid of this invention can be the complement of a nucleic acid 
described herein. 
0138 A “biologically active fragment' or “active frag 
ment as used herein includes a polypeptide of this invention 
that comprises a Sufficient number of amino acids to have one 
or more of the biological activities of the polypeptides of this 
invention. Such biological activities can include, but are not 
limited to, in any combination, binding activity, immuno 
modulating activity, virulence activity and/or immunogenic 
activity, as well as any other activity now known or later 
identified for the polypeptides and/or fragments of this inven 
tion. A fragment of a polypeptide of this invention can be 
produced by methods well known and routine in the art. 
Fragments of this invention can be produced, for example, by 
enzymatic or other cleavage of naturally occurring peptides 
or polypeptides or by synthetic protocols that are well known. 
Such fragments can be tested for one or more of the biological 
activities of this invention according to the methods described 
herein, which are routine methods for testing activities of 
polypeptides, and/or according to any art-known and routine 
methods for identifying Such activities. Such production and 
testing to identify biologically active fragments of the 
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polypeptides described herein would be well within the scope 
of one of ordinary skill in the art and would be routine. 
0.139 Fragments of the polypeptides of this invention are 
preferably at least about ten amino acids in length and retain 
one or more of the biological activities (e.g., immunomodu 
lating; virulence activities) and/or the immunological activi 
ties of the A35R protein. Examples of the fragments of this 
invention include, but are not intended to be limited to, the 
following fragments identified by the amino acid number as 
shown in the Sequence Listing for SEQ ID NO:2: Amino 
acids 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 
80-90, 90-100, 110-120, 120-130, 130-140, 140-150, 150 
160, 160-170, 170-180, 180-190, 190-200, 200-210, 210 
220, 220-230, 230-240, 240-250, 1-25, 1-50, 1-67, 1-75, 
1-100, 1-125, 1-135, 1-145, 1-150, 1-160, 1-170, 1-180, 
1-190, 1-200, 1-250, 68-180, 183-223,50-100, 100-200, 200 
250, etc. 
0140. It is understood that this list is exemplary only and 
that a fragment of this invention can be any amino acid 
sequence containing any combination of contiguous amino 
acids that are numbered in the Sequence Listing as amino 
acids 1 through 250 even if that combination is not specifi 
cally recited as an example herein. It is also understood that 
these fragments can be combined in any order or amount. For 
example, fragment 1-10 can be combined with fragment 
10-20 to produce a fragment of amino acids 1-20. As another 
example, fragment 1-20 can be combined with fragment 
50-60 to produce a single fragment of this invention having 31 
amino acids (AA 10-20 and AA 50-60). Also fragments can 
be present in multiple numbers and in any combination in a 
fragment of this invention. Thus, for example, fragment 
1-150 can be combined with a second fragment 1-150 and/or 
combined with fragment 225-230 to produce a fragment of 
this invention. Other exemplary fragments of this invention 
include amino acids 1-60 of variola virus; and the amino acid 
sequence: YDDLDISIMDFIGPY (SEQID NO:44). 
0.141. The terms “homology.” “identity” and “comple 
mentarity” as used herein refer to a degree of similarity 
between two or more sequences. There may be partial homol 
ogy or complete homology (i.e., identity). A partially comple 
mentary sequence that at least partially inhibits an identical 
sequence from hybridizing to a target nucleic acid is referred 
to as “substantially homologous.” The inhibition of hybrid 
ization of the completely complementary sequence to the 
target sequence can be examined using a hybridization assay 
(Southern or Northern blot, solution hybridization and the 
like) under conditions of low stringency. A Substantially 
homologous sequence or hybridization probe will compete 
for and inhibit the binding of a completely homologous 
sequence to the target sequence under conditions of low strin 
gency, as this term is known in the art. This is not to say that 
conditions of low stringency are such that non-specific bind 
ing is permitted; low Stringency conditions require that the 
binding of two sequences to one another be a specific (i.e., 
selective) interaction. The absence of non-specific binding 
can be tested by the use of a second target sequence that lacks 
even a partial degree of complementarity (e.g., less than about 
30% identity). In the absence of non-specific binding, the 
probe will not hybridize to the second non-complementary 
target Sequence. 
0142. The term “hybridization' as used herein refers to 
any process by which a first strand of nucleic acid binds with 
a second strand of nucleic acid through base pairing. Nucleic 
acids encoding the polypeptides and/or fragments of this 
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invention can be detected by DNA-DNA or DNA-RNA 
hybridization and/or amplification using probes, primers and/ 
or fragments of polynucleotides encoding the polypeptides 
and/or fragments of this invention and/or designed to detect 
and/or amplify the nucleic acids of this invention. 
0143. The term “hybridization complex' as used herein 
refers to a complex formed between two nucleic acid 
sequences by virtue of the formation of hydrogen bonds 
between complementary G and C bases and between comple 
mentary A and T bases; these hydrogen bonds may be further 
stabilized by base Stacking interactions. The two complemen 
tary nucleic acid sequences hydrogen bond in an antiparallel 
configuration. A hybridization complex may be formed in 
solution (e.g., Cotor Rotanalysis) or between one nucleic acid 
sequence present in Solution and another nucleic acid 
sequence immobilized on a solid Support (e.g., paper, mem 
branes, filters, chips, pins or glass slides, or any other appro 
priate substrate to which cells and/or nucleic acids have been 
fixed). 
0144. The term “nucleotide sequence” refers to a het 
eropolymer of nucleotides or the sequence of these nucle 
otides. The terms “nucleic acid.” “oligonucleotide' and 
"polynucleotide are also used interchangeably herein to 
refer to a heteropolymer of nucleotides. Generally, nucleic 
acid segments provided by this invention may be assembled 
from fragments of the genome and short oligonucleotide link 
ers, or from a series of oligonucleotides, or from individual 
nucleotides, to provide a synthetic nucleic acid which is 
capable of being expressed in a recombinant transcriptional 
unit comprising regulatory elements derived from a microbial 
or viral operon, or a eukaryotic gene. Nucleic acids of this 
invention can comprise a nucleotide sequence that can be 
identical in sequence to the sequence which is naturally 
occurring or, due to the well-characterized degeneracy of the 
nucleic acid code, can include alternative codons that encode 
the same amino acid as that which is found in the naturally 
occurring sequence. Furthermore, nucleic acids of this inven 
tion can comprise nucleotide sequences that can include 
codons which represent conservative substitutions of amino 
acids as are well known in the art, such that the biological 
activity of the resulting polypeptide and/or fragment is 
retained. 
(0145 The term “probe' or “primer' includes naturally 
occurring and/or recombinant and/or chemically synthesized 
single- and/or double-stranded nucleic acids. They can be 
labeled for detection by nick translation, Klenow fill-in reac 
tion, PCR and/or other methods well known in the art. Probes 
and primers of the present invention, their preparation and/or 
labeling are described in Sambrook et al. 1989. Molecular 
Cloning: A Laboratory Manual, Cold Spring Harbor Labo 
ratory, NY and Ausubel et al. 1989. Current Protocols in 
Molecular Biology, John Wiley & Sons, New York N.Y., both 
of which are incorporated herein by reference in their entirety 
for these teachings. 
0146 The term “stringent” as used herein refers to hybrid 
ization conditions that are commonly understood in the art to 
define the conditions of the hybridization procedure. Strin 
gency conditions can below, high or medium, as those terms 
are commonly know in the art and well recognized by one of 
ordinary skill. In various embodiments, stringent conditions 
can include, for example, highly stringent (i.e., high Strin 
gency) conditions (e.g., hybridization in 0.5 MNaHPO, 7% 
sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and 
washing in 0.1xSSC/0.1% SDS at 68° C.), and/or moderately 
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stringent (i.e., medium stringency) conditions (e.g., washing 
in 0.2xSSC/0.1% SDS at 42° C.). 
0147 Amplification” as used herein includes the produc 
tion of multiple copies of a nucleic acid molecule and is 
generally carried out using polymerase chain reaction (PCR) 
and/or any other amplification technologies as are well 
known in the art (Dieffenbach and Dveksler. 1995. PCR 
Primer, a Laboratory Manual, Cold Spring Harbor Press, 
Plainview, N.Y.). 
0.148. The term “sample as used herein is used in its 
broadest sense. A biological sample Suspected of containing a 
polypeptide, fragment, antibody and/or nucleic acid of this 
invention can be any biological fluid, an extract from a cell, an 
extracellular matrix isolated from a cell, a cell (in solution or 
bound to a solid Support), a tissue, a tissue print, and the like. 
A sample of this invention can also include a Substance not 
obtained from the body of a subject of this invention. 
Examples of Such a sample include but are not limited to, a 
water or fluid sample, a food or foodstuff sample, a plant or 
plant material sample, a soil or rock sample, an animal or 
animal material sample, an animal bedding sample, an animal 
cage sample, air sample a soil or dirt sample, a cloth, paperor 
other material used to Swab, wipe, dust or clean a surface, an 
effluent sample, etc. 
0.149 “Effective amount” as used herein refers to an 
amount of a compound, agent, Substance or composition of 
this invention that is sufficient to produce a desired effect, 
which can be a therapeutic effect. The effective amount will 
vary with the age, general condition of the subject, the sever 
ity of the condition being treated, the particular compound, 
agent, Substance or composition administered, the duration of 
the treatment, the nature of any concurrent treatment, the 
pharmaceutically acceptable carrier used if any, and like fac 
tors within the knowledge and expertise of those skilled in the 
art. As appropriate, an “effective amount” in any individual 
case can be determined by one of ordinary skill in the art by 
reference to the pertinent texts and literature and/or by using 
routine experimentation. (Remington, The Science And Prac 
tice of Pharmacy (20th ed. 2000)). 
0150. A “pharmaceutically acceptable' component such 
as a salt, carrier, excipient or diluent of a composition accord 
ing to the present invention is a component that (i) is compat 
ible with the other ingredients of the composition in that it can 
be combined with the compositions of the present invention 
without rendering the composition unsuitable for its intended 
purpose, and (ii) is suitable for use with Subjects as provided 
herein without undue adverse side effects (such as toxicity, 
irritation, and allergic response). Side effects are “undue' 
when their risk outweighs the benefit provided by the com 
position. Non-limiting examples of pharmaceutically accept 
able components (e.g., pharmaceutically acceptable carriers) 
include, without limitation, any of the standard pharmaceu 
tical carriers such as phosphate buffered saline Solutions, 
water, emulsions such as oil/water emulsion, microemulsions 
and various types of wetting agents. In particular, it is 
intended that a pharmaceutically acceptable carrier be a ster 
ile carrier that is formulated for administration to or delivery 
into a subject of this invention. 
0151. Furthermore, any of the compositions of this inven 
tion can comprise a pharmaceutically acceptable carrier and a 
suitable adjuvant. As used herein, “suitable adjuvant” 
describes an adjuvant capable of being combined with the 
polypeptide and/or fragment and/or nucleic acid of this inven 
tion to further enhance an immune response without delete 
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rious effect on the subject or the cell of the subject. A suitable 
adjuvant can be, but is not limited to, MONTANIDE ISA51 
(Seppic, Inc., Fairfield, N.J.), SYNTEX adjuvant formulation 
1 (SAF-1), composed of 5 percent (wt/vol) squalene (DASF, 
Parsippany, N.J.), 2.5 percent Pluronic, L121 polymer (Ald 
rich Chemical, Milwaukee), and 0.2 percent polysorbate 
(Tween 80, Sigma) in phosphate-buffered saline. Other suit 
able adjuvants are well known in the art and include QS-21, 
Freund's adjuvant (complete and incomplete), alum, alumi 
num phosphate, aluminum hydroxide, N-acetyl-muramyl-L- 
threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-mu 
ramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as 
nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L- 
alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphospho 
ryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE) 
and RIBI, which contains three components extracted from 
bacteria, monophosphoryl lipid A, trealose dimycolate and 
cell wall skeleton (MPL+TDM+CWS) in 2% squalene/ 
Tween 80 emulsion. 
0152 The compositions of the present invention can also 
include other medicinal agents, pharmaceutical agents, car 
riers, diluents, immunostimulatory cytokines, etc. Actual 
methods of preparing such dosage forms are known, or will be 
apparent, to those skilled in this art. 
0153. A “tumor antigen' of this invention (i.e., an antigen 
specifically associated with tumor cells) of this invention can 
include, for example, HER2/neu and BRCA1 antigens for 
breast cancer, MART-1/MelanA, gp100, tyrosinase, TRP-1, 
TRP-2, NY-ESO-1, CDK-4, B-catenin, MUM-1, Caspase-8, 
KIAA0205, HPVE7, SART-1, PRAME, and p15 antigens, 
members of the MAGE family, the BAGE family (such as 
BAGE-1), the DAGE/PRAME family (such as DAGE-1), the 
GAGE family, the RAGE family (such as RAGE-1), the 
SMAGE family, NAG, TAG-72, CA125, mutated proto-on 
cogenes such as p21 ras, mutated tumor Suppressor genes Such 
as p53: tumor associated viral antigens (e.g., HPV 16 E7), the 
SSX family, HOM-MEL-55, NY-COL-2, HOM-HD-397, 
HOM-RCC-1.14, HOM-HD-21, HOM-NSCLC-11, HOM 
MEL-2.4, HOM-TES-11, RCC-3.1.3, NY-ESO-1, and the 
SCP family. Members of the MAGE family include, but are 
not limited to, MAGE-1, MAGE-2, MAGE-3, MAGE-4 and 
MAGE-11. Members of the GAGE family include, but are not 
limited to, GAGE-1, GAGE-6, See, e.g., review by Van den 
Eynde and van der Bruggen (1997) in Curr. Opin. Immunol. 9: 
684-693, Sahin et al. (1997) in Curr. Opin. Immunol. 9: 709 
716, and Shawler et al. (1997), the entire contents of which 
are incorporated by reference herein for their teachings of 
cancer antigens. 
0154 The tumor antigen can also be, but is not limited to, 
human epithelial cell mucin (Muc-1; a 20 amino acid core 
repeat for Muc-1 glycoprotein, present on breast cancer cells 
and pancreatic cancer cells), MUC-2, MUC-3, MUC-18, the 
Ha-ras oncogene product, carcino-embryonic antigen (CEA), 
the raf oncogene product, CA-125, GD2, GD3, GM2, TF, 
sTn, gp75, EBV-LMP 1 & 2, HPV-F4, 6, 7, prostatic serum 
antigen (PSA), prostate-specific membrane antigen (PSMA), 
alpha-fetoprotein (AFP), CO17-1A, GA733, gp72, p53, the 
ras oncogene product, B-HCG, gp43, HSP-70, p17 mel, HSP 
70, gp43, HMW, HOJ-1, melanoma gangliosides, TAG-72, 
mutated proto-oncogenes Such as p21 ras, mutated tumor Sup 
pressor genes such as p53, estrogen receptor, milkfat globu 
lin, telomerases, nuclear matrix proteins, prostatic acid phos 
phatase, protein MZ2-E, polymorphic epithelial mucin 
(PEM), folate-binding-protein LK26, truncated epidermal 
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growth factor receptor (EGFR), Thomsen-Friedenreich (T) 
antigen, GM-2 and GD-2 gangliosides, polymorphic epithe 
lial mucin, folate-binding protein LK26, human chorionic 
gonadotropin (HCG), pancreatic oncofetal antigen, cancer 
antigens 15-3, 19-9,549, 195, squamous cell carcinoma anti 
gen (SCCA), ovarian cancer antigen (OCA), pancreas cancer 
associated antigen (PaA), mutant K-ras proteins, mutant p53, 
and chimeric protein p210,- and tumor associated viral 
antigens (e.g., HPV 16 E7). 
0155 The tumor antigen of this invention can also be an 
antibody produced by a B cell tumor (e.g., B cell lymphoma; 
B cell leukemia; myeloma; hairy cell leukemia), a fragment 
of such an antibody, which contains an epitope of the idiotype 
of the antibody, a malignant B cell antigen receptor, a malig 
nant B cell immunoglobulin idiotype, a variable region of an 
immunoglobulin, a hyperVariable region or complementarity 
determining region (CDR) of a variable region of an immu 
noglobulin, a malignant T cell receptor (TCR), a variable 
region of a TCR and/or a hypervariable region of a TCR. In 
one embodiment, the cancer antigen of this invention can be 
a single chain antibody (scEv), comprising linked V, and V, 
domains, which retains the conformation and specific binding 
activity of the native idiotype of the antibody. 
0156 The present invention is in no way limited to the 
tumor antigens listed herein. Other tumor antigens be identi 
fied, isolated and cloned by methods known in the art Such as 
those disclosed in U.S. Pat. No. 4,514,506, the entire contents 
of which are incorporated by reference herein. 
(O157. The cancer to be treated by the methods of this 
invention can be, but is not limited to, B cell lymphoma, T cell 
lymphoma, myeloma, leukemia, hematopoietic neoplasias, 
thymoma, lymphoma, sarcoma, lung cancer, liver cancer, 
non-Hodgkins lymphoma, Hodgkins lymphoma, uterine can 
cer, adenocarcinoma, breast cancer, pancreatic cancer, colon 
cancer, lung cancer, renal cancer, bladder cancer, liver cancer, 
prostate cancer, ovarian cancer, primary or metastatic mela 
noma, squamous cell carcinoma, basal cell carcinoma, brain 
cancer, angiosarcoma, hemangiosarcoma, head and neck car 
cinoma, thyroid carcinoma, soft tissue sarcoma, bone sar 
coma, testicular cancer, uterine cancer, cervical cancer, gas 
trointestinal cancer, and any other cancer now known or later 
identified (see, e.g., Rosenberg (1996) Ann. Rev. Med. 
47:481–491, the entire contents of which are incorporated by 
reference herein). 
0158 Infectious and/or pathogenic agents of this inven 
tion can include, but are not limited to, Hepadnaviridae, 
including hepatitis A, B, C, D, E, F, G, etc. (e.g., HBSAg, 
HBcAg., HBeAg); Flaviviridae, including human hepatitis C 
virus (HCV), yellow fever virus and dengue viruses: Retro 
viridae, including human immunodeficiency viruses (HIV) 
and human T lymphotropic viruses (HTLV1 and HTLV2); 
Herpesviridae, including herpes simplex viruses (HSV-1 and 
HSV-2), Epstein Barr virus (EBV), cytomegalovirus, vari 
cella-Zoster virus (VZV), human herpes virus 6 (HHV-6) 
human herpes virus 8 (HHV-8), and herpes B virus: 
Papovaviridae, including human papilloma viruses; Rhab 
doviridae, including rabies virus; Paramyxoviridae, includ 
ing respiratory syncytial virus; Reoviridae, including rotavi 
ruses; Bunyaviridae, including hantaviruses; Filoviridae, 
including Ebola virus: Adenoviridae: Parvoviridae, including 
parvovirus B-19; Arenaviridae, including Lassa virus; Orth 
omyxoviridae, including influenza viruses; Poxyiridae, 
including Orf virus, molluscum contageosum virus, Smallpox 
virus and Monkeypox virus; Togaviridae, including Venezu 
US 2012/O294.896 A1 
elan equine encephalitis virus; Coronaviridae, including 
corona viruses such as the severe acute respiratory syndrome 
(SARS) virus; Picornaviridae including polioviruses; rhi 
noviruses; orbiviruses; picodnaviruses; encephalomyocardi 
tis virus (EMV); parainfluenza viruses, adenoviruses, cox 
sackieviruses, echoviruses, rubeola virus, rubella virus, 
human papillomaviruses, canine distemper virus, canine con 
tagious hepatitis virus, feline calicivirus, feline rhinotrache 
itis virus, TGE virus (swine), foot and mouth disease virus, 
simian virus 5, human parainfluenza virus type 2, human 
metapneuomovirus, enteroviruses, and any other pathogenic 
virus now known or later identified (see, e.g., Fundamental 
Virology, Fields et al., Eds., 3" ed., Lippincott-Raven, New 
York, 1996, the entire contents of which are incorporated by 
reference herein for the teachings of pathogenic viruses). 
0159. A pathogenic microorganism of this invention can 
include but is not limited to, Rickettsia, Chlamydia, Myco 
bacteria, Clostridia, Corynebacteria, Mycoplasma, Ureoa 
plasma, Legionella, Shigella, Salmonella, pathogenic 
Escherichia coli species, Bordatella, Neisseria, Treponema, 
Bacillus, Haemophilus, Moraxella, Vibrio, Staphylococcus 
spp., Streptococcus spp., Campylobacter spp., Borrelia spp., 
Leptospira spp., Erlichia spp., Klebsiella spp., Pseudomonas 
spp., Helicobacter spp., and any other pathogenic microor 
ganism now known or later identified (see, e.g., Microbiol 
ogy, Davis etal, Eds., 4" ed., Lippincott, New York, 1990, the 
entire contents of which are incorporated herein by reference 
for the teachings of pathogenic microorganisms). 
(0160 Specific examples of microorganisms include, but 
are not limited to, Helicobacter pylori, Chlamydia pneumo 
niae, Chlamydia trachomatis, Ureaplasma urealyticum, 
Mycoplasma pneumoniae, Staphylococcus aureus, Strepto 
coccus pyogenes, Streptococcus pneumoniae, Streptococcus 
viridans, Enterococcus faecalis, Neisseria meningitidis, 
Neisseria gonorrhoeae, Treponema pallidum, Bacillus 
anthracis, Salmonella typhi, Vibrio cholera, Pasteurella pes 
tis, Pseudomonas aeruginosa, Campylobacter jejuni, 
Clostridium difficile, Clostridium botulinum, Mycobacterium 
tuberculosis, Borrelia burgdorferi, Haemophilus ducreyi, 
Corynebacterium diphtheria, Bordetella pertussis, Borde 
tella parapertussis, Bordetella bronchiseptica, Haemophilus 
influenza, and enterotoxic Escherichia coli. 
0161 Pathogenic protozoa can include, but are not limited 
to, Plasmodium species (e.g., malaria antigens), Babeosis 
species, Schistosoma species, Trypanosoma species, Pneu 
mocystis carnii, Toxoplasma species, Leishmania species, 
and any other protozoan pathogen now known or later iden 
tified. 
0162 Also included are pathogenic yeast and fungi, 
examples of which can be, but are not limited to, Aspergillus 
species, Candida species, Cryptococcus species. Histo 
plasma species, Coccidioides species, and any other patho 
genic fungus now known or later identified. 
0163 Transplantation antigens of this invention include, 
but are not limited to, different antigenic specificities of HLA 
A, B and C Class I proteins. Different antigenic specificities 
of HLA-DR, HLA-DQ, HLA-DP and HLA-DW Class II 
proteins can also be used (WHONomenclature Committee, 
Immunogenetics 16:135 (1992); Hensen et al., in Fundamen 
tal Immunology, Paul, Ed., pp. 577-628, Raven Press, New 
York, 1993; NIH GenBank and EMBL databases). 
0164. The present invention also contemplates the treat 
ment or prevention of allergies and/or allergic reaction, 
caused by various allergens, which can include, but are not 
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limited to, environmental allergens such as dust mite aller 
gens; plant allergens Such as pollen, including ragweed pol 
len; insect allergens such as bee and ant venom; and animal 
allergens such as cat dander, dog dander and animal saliva 
allergens. 
0.165 An “immunomodulatory molecule' of this inven 
tion can be, but is not limited to an immunostimulatory cytok 
ine that can be, but is not limited to, GM/CSF, interleukin-2, 
interleukin-12, interferon-gamma, interleukin-4, tumor 
necrosis factor-alpha, interleukin-1, hematopoietic factor 
flt3L, CD40L, B7.1 co-stimulatory molecules and B7.2 co 
stimulatory molecules. 
0166 Additional examples of an immunomodulatory 
molecule of this invention include the adjuvants of this inven 
tion, including, for example, SYNTEX adjuvant formulation 
1 (SAF-1) composed of 5 percent (wt/vol) squalene (DASF, 
Parsippany, N.J.), 2.5 percent Pluronic, L121 polymer (Ald 
rich Chemical, Milwaukee), and 0.2 percent polysorbate 
(Tween 80, Sigma) in phosphate-buffered saline. Suitable 
adjuvants also include an aluminum salt Such as aluminum 
hydroxide gel (alum), aluminum phosphate, or algannmulin, 
but may also be a salt of calcium, iron or Zinc, or may be an 
insoluble Suspension of acylated tyrosine, or acylated Sugars, 
cationically or anionically derivatized polysaccharides, or 
polyphosphaZenes. 
0167. Other adjuvants are well known in the art and 
include QS-21, Freund's adjuvant (complete and incom 
plete), aluminum hydroxide, N-acetyl-muramyl-L-threonyl 
D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl 
D-isoglutamine (CGP 11637, referred to as nor-MDP), 
N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2- 
(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)- 
ethylamine (CGP 19835A, referred to as MTP-PE) and RIBI, 
which contains three components extracted from bacteria, 
monophosphoryl lipid A, trealose dimycolate and cell wall 
skeleton (MPL+TDM+CWS) in 2% squalene/Tween 80 
emulsion. 
0168 Additional adjuvants can include, for example, a 
combination of monophosphoryl lipid A, preferably 3-de-O- 
acylated monophosphoryl. lipid A (3D-MPL) together with 
an aluminum salt. An enhanced adjuvant system involves the 
combination of a monophosphoryl lipid A and a saponin 
derivative, particularly the combination of QS21 and 
3D-MPL as disclosed in PCT publication number WO 
94/00153 (the entire contents of which are incorporated 
herein by reference), or a less reactogenic composition where 
the QS21 is quenched with cholesterol as disclosed in PCT 
publication number WO 96/33739 (the entire contents of 
which are incorporated herein by reference). A particularly 
potent adjuvant formulation involving QS21 3D-MPL & 
tocopherol in an oil in water emulsion is described in PCT 
publication number WO95/17210 (the entire contents of 
which are incorporated herein by reference). In addition, the 
nucleic acid of this invention can include an adjuvant by 
comprising a nucleotide sequence encoding an A35R protein 
or active fragment thereof of this invention and a nucleotide 
sequence that provides an adjuvant function, such as CpG 
sequences. Such CpG sequences, or motifs, are well known in 
the art. 
(0169. The terms “treat,” “treating” or “treatment” include 
any type of action that imparts a modulating effect, which, for 
example, can be a beneficial effect, to a subject afflicted with 
a disorder, disease, condition or illness, including improve 
ment in the disorder, disease, condition or illness of the sub 
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ject (e.g., in one or more symptoms), delay in the progression 
of the disorder, disease, condition or illness, prevention or 
delay of the onset of the disorder, disease, condition or illness, 
and/or change in clinical parameters, disorder, disease, con 
dition or illness status, etc., as would be well known in the art. 
0170 As used herein, the term “antibody' includes intact 
immunoglobulin molecules as well as fragments thereof that 
are capable of binding the epitopic determinant of an antigen 
(i.e., antigenic determinant). Antibodies that bind the 
polypeptides of this invention are prepared using intact 
polypeptides or fragments as the immunizing antigen. The 
polypeptide or fragment used to immunize an animal can be 
derived from enzymatic cleavage, recombinant expression, 
isolation from biological materials, synthesis, etc., and can be 
conjugated to a carrier protein, if desired. Commonly used 
carriers that are chemically coupled to peptides and proteins 
for the production of antibody include, but are not limited to, 
bovine serum albumin, thyroglobulin and keyhole limpet 
hemocyanin. The coupled peptide or protein is then used to 
immunize the animal (e.g., a mouse, rat, or rabbit). The 
polypeptide or peptide antigens can also be administered with 
an adjuvant, as described herein and as otherwise known in 
the art. 
0171 An antibody of this invention can be any type of 
immunoglobulin, including IgG, IgM, IgA, Ig|D, and/or IgE. 
The antibody can be monoclonal or polyclonal and can be of 
any species of origin, including, for example, mouse, rat, 
rabbit, horse, goat, sheep or human, or can be a chimeric or 
humanized antibody (e.g., Walker et al., Molec. Immunol. 
26:403-11 (1989)). The antibodies can be recombinant mono 
clonal antibodies produced according to the methods dis 
closed in U.S. Pat. No. 4,474,893 or U.S. Pat. No. 4,816,567. 
The antibodies can also be chemically constructed according 
to methods disclosed in U.S. Pat. No. 4,676,980. The anti 
body can further be a single chain antibody (e.g., ScPV) or 
bispecific antibody. 
0172 Antibody fragments included within the scope of 
the present invention include, for example, Fab, F(ab')2, and 
Fc fragments, and the corresponding fragments obtained 
from antibodies other than IgG. Such fragments can be pro 
duced by known techniques. For example, F(ab')2 fragments 
can be produced by pepsin digestion of the antibody mol 
ecule, and Fab fragments can be generated by reducing the 
disulfide bridges of the F(ab')2 fragments. Alternatively, Fab 
expression libraries can be constructed to allow rapid and 
easy identification of monoclonal Fab fragments with the 
desired specificity (Huse et al., (1989) Science 254:1275 
1281). Antibodies can also be obtained by phage display 
techniques known in the art or by immunizing a heterologous 
host with a cell containing an epitope of interest. 
0173 The polypeptide, fragment or antigenic epitope that 
is used as an immunogen can be modified or administered in 
an adjuvant in order to increase antigenicity. Methods of 
increasing the antigenicity of a protein or peptide are well 
known in the art and include, but are not limited to, coupling 
the antigen with a heterologous protein (Such as globulin or 
B-galactosidase) or through the inclusion of an adjuvant dur 
ing immunization. 
0.174 For example, for the production of antibodies, vari 
ous hosts including goats, rabbits, rats, mice, humans, and 
others, can be immunized by injection with the polypeptides 
and/or fragments of this invention, with or without a carrier 
protein. Additionally, various adjuvants may be used to 
increase the immunological response. Such adjuvants 
17 
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include, but are not limited to, Freund's complete and incom 
plete adjuvants, mineral gels such as aluminum hydroxide, 
and Surface-active Substances such as lysolecithin, pluronic 
polyols, polyanions, peptides, oil emulsions, keyhole limpet 
hemocyanin, and dinitrophenol. Among adjuvants used in 
humans, BCG (bacilli Calmette-Guerin) and Corynebacte 
rium parvum are especially preferable. 
0.175 Monoclonal antibodies can be produced in a hybri 
doma cell line according to the technique of Kohler and 
Milstein (Nature 265:495-97 (1975)). Other techniques for 
the production of monoclonal antibodies include, but are not 
limited to, the human B-cell hybridoma technique, and the 
EBV-hybridoma technique (Kozbor et al. 1985. J. Immunol. 
Methods 81:31-42; Cote et al. 1983. Proc. Natl. Acad. Sci. 
80:2026-2030; Cole et al. 1984. Mol. Cell Biol. 62:109-120). 
0176 For example, to produce monoclonal antibodies, a 
Solution containing the appropriate antigen can be injected 
into a mouse and, after a Sufficient time, the mouse sacrificed 
and spleen cells obtained. The spleen cells are then immor 
talized by fusing them with myeloma cells or with lymphoma 
cells, typically in the presence of polyethylene glycol, to 
produce hybridoma cells. The hybridoma cells are then grown 
in a suitable medium and the Supernatant Screened for mono 
clonal antibodies having the desired specificity. Monoclonal 
Fab fragments can be produced in a bacterial cell Such as E. 
coli by recombinant techniques known to those skilled in the 
art (e.g., Huse, Science 246:1275-81 (1989)). Any one of a 
number of methods well known in the art can be used to 
identify the hybridoma cell, which produces an antibody with 
the desired characteristics. These include screening the hybri 
domas by ELISA assay, Western blot analysis, or radioimmu 
noassay. Hybridomas Secreting the desired antibodies are 
cloned and the class and Subclass are identified using standard 
procedures known in the art. 
0177. For polyclonal antibodies, antibody-containing 
serum is isolated from the immunized animal and is screened 
for the presence of antibodies with the desired specificity 
using any of the well known procedures as described herein. 
0.178 The present invention further provides antibodies of 
this invention in detectably labeled form. Antibodies can be 
detectably labeled through the use of radioisotopes, affinity 
labels (such as biotin, avidin, etc.), enzymatic labels (such as 
horseradish peroxidase, alkaline phosphatase, etc.) fluores 
cence labels (such as FITC or rhodamine, etc.), paramagnetic 
atoms, gold beads, etc. Such labeling procedures are well 
known in the art. The labeled antibodies of the present inven 
tion can be used for in vitro, in vivo, and in situ assays to 
identify a polypeptide and/or fragment of this invention in a 
sample. 
0179. In some embodiments, the present invention further 
provides the above-described antibodies immobilized on a 
Solid Support (e.g., beads, plates, slides or wells formed from 
materials such as latex or polystyrene). Examples of Such 
Solid Supports include plastics Such as polycarbonate, com 
plex carbohydrates Such as agarose and Sepharose, acrylic 
resins and Such as polyacrylamide and latex beads. Tech 
niques for coupling antibodies to Such solid Supports are well 
known in the art (Weir et al., Handbook of Experimental 
Immunology 4th Ed., Blackwell Scientific Publications, 
Oxford, England, Chapter 10 (1986)). Antibodies can like 
wise be conjugated to detectable groups such as radiolabels 
(e.g., S.I. ''I), enzyme labels (e.g., horseradish peroxi 
dase, alkaline phosphatase), and fluorescence labels (e.g., 
fluorescein) in accordance with known techniques. Determi 
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nation of the formation of an antibody/antigen complex in the 
methods of this invention can be by detection of, for example, 
precipitation, agglutination, flocculation, radioactivity, color 
development or change, fluorescence, luminescence, etc., as 
is well know in the art. 
0180. In addition, techniques developed for the production 
of chimeric antibodies or humanized antibodies by splicing 
mouse antibody genes to human antibody genes to obtain a 
molecule with appropriate antigen specificity and biological 
activity can be used (Morrison et al. 1984. Proc. Natl. Acad. 
Sci. 81:6851-6855; Neuberger et al. 1984. Nature 312:604 
608: Takeda et al. 1985. Nature 314:452-454). Alternatively, 
techniques described for the production of single chain anti 
bodies can be adapted, using methods known in the art, to 
produce single chain antibodies specific for the polypeptides 
and fragments of this invention. Antibodies with related 
specificity, but of distinct idiotypic composition, can be gen 
erated by chain shuffling from random combinatorial immu 
noglobin libraries (Burton 1991. Proc. Natl. Acad. Sci. 
88: 11120-3). 
0181 Various immunoassays can be used for screening to 
identify antibodies having the desired specificity for the pro 
teins and peptides of this invention. Numerous protocols for 
competitive binding or immunoradiometric assays using 
either polyclonal or monoclonal antibodies with established 
specificity are well known in the art. Such immunoassays 
typically involve the measurement of complex formation 
between an antigen and its specific antibody (e.g., antigen/ 
antibody complex formation). For example, a two-site, 
monoclonal-based immunoassay utilizing monoclonal anti 
bodies reactive to two non-interfering epitopes on the pro 
teins or peptides of this invention can be used, as well as a 
competitive binding assay. 
0182. The present invention is more particularly described 
in the following examples, which are intended as illustrative 
only since numerous modifications and variations therein will 
be apparent to those skilled in the art. 
EXAMPLES 
I. Immunoregulatory Activity of Poxvirus A35R Pro 
tein 
0183 Cell Tropism. 
0184. Several cell types were split into two groups of equal 
number for infection. One group was infected with wild-type 
(Western Reserve or WR) vaccinia virus and the other with 
the A35R deletion mutant (vaccinia virus that does not con 
tain the A35R protein). Cells were infected at a multiplicity of 
infection (MOI) of 1. Cells were then incubated approxi 
mately 20 hours. Three freeze-thaw cycles were then per 
formed to release newly formed virus particles. Measure of 
replication was accomplished by titering the cell lysates on a 
monolayer of BS-C-1 cells and counting the plaques that 
formed 40 hours later. 
0185. Harvest/Infection for Assays. 
0186. A 5-9 month old rat (strain: Lewis X from DCM) 
was injected i.p. with 20 g of C. parvum in 5 ml of HBSS. 
Three days later the rat was sacrificed and macrophages (peri 
toneal exudates cells) were harvested. The macrophages were 
counted and aliquoted in three 15 ml conical tubes prior to a 
five hour infection incubationatan MOI of 2. Each treatment 
group was then washed and plated in a 96 well format. Six 1:2 
dilutions were performed before incubation with 500 nM 
GPMBP for 30 minutes. 25,000 Lewis rat CD4+ RSL-11 
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clones specific for myelin basic protein were added to each 
well in 80 ul volumes. The plates were incubated for 24 hours 
at 37°C., 5.0% CO. After incubation, 150 ul of supernatant 
were transferred to an empty 96-well plate and frozen for later 
analysis. 
0187 Nitric Oxide Assay. 
0188 Fifty microliters of the harvested supernatant were 
transferred into another 96-well plate followed by the addi 
tion of Griess Reagent (1% sulfanilamide-0.1% N-1-naph 
thylethylenediamine in 2.5% phosphoric acid) into each well. 
The absorbance was read at 540 nm at time intervals begin 
ning after a five minute incubation at room temperature. 
Maximum readings were achieved after a 1.5-2 hour incuba 
tion. 
(0189 IL-2 Bioassay. 
0.190 Fifty microliters of the harvested supernatants were 
transferred into another 96-well plate. A total of 50,000 
CTLL clones (ATCC TIB-214) were washed, resuspended in 
cRPMI, and added to the wells. After 48 hours of incubation 
at 37°C., 5.0% CO., 10ul of MTS/PMS was added to every 
sample. The absorbance was read at 492 nm filtered using 690 
nm as the reference wavelength. 
(0191 VA35A Mutant Virus. 
0.192 To construct the VA35A mutant virus, wild-type 
(WR)-infected cells were transfected with a recombinant 
PCR product containing A34R and A3.6R flanking sequences 
with the intervening A35R gene replaced by the E. coli gpt 
gene. The recombinant VA35A was selected in medium con 
taining mycophenolic acid (Roper. 2006. “Characterization 
of the vaccinia virus A35R protein and its role in virulence'.J. 
Virol. 80:306-313; the entire contents of which is incorpo 
rated by reference herein for studies to characterize the pox 
virus A35R protein). 
(0193 Cell Tropism. 
0194 The growth of wild-type and A35R deletion mutant 
virus was studied in 18 cell types from six different animals 
(rats, rabbits, mice, monkeys, hamsters and humans. In one 
study, the following cell lines were tested: BS-C-1 cells (Afri 
can green monkey cells), old rat splenocytes, young rat sple 
nocytes, rat thymocytes, differentiated PC-12 cells, undiffer 
entiated PC-12 cells, activated RSL-11 cells, resting RSL-11 
cells, PEC, CTLL, brain cells (Heldtilt), HFF cells and R1-T 
cells. An A35A/wild-type ratio of replication was established. 
These studies demonstrated that PECs, CTLLs and R1-Ts 
may have tropism where the deletion mutant had a least a 
2-fold greater Success replicating than wild-type. Equal rep 
lication was consistent in BS-C-1 cells, which were used as 
the control. 
(0195 Attenuation in Mice. 
0196. Four treatment groups (six mice each) of 14-17 g. 5 
week-old female BALB/c mice were anesthetized and intra 
nasally challenged with 10 particle forming units (pfu) of 
wildtype (WR), 35Res (a rescue virus produced by engineer 
ing a wild-type A35R gene back into the VA35A genome) or 
35Del (the VA35A mutant virus), or with PBS. The weight of 
the mice in each group was measured over a period of days. 
Over a span of 12 days, the A35R deletion treatment group 
almost paralleled the PBS control group in that gradual 
weight gain of 10-11% occurred. The A35-Res and WR 
groups showed an average weight loss of 16-26%, respec 
tively, by day 12. 
(0197) Nitric Oxide and IL-2 Bioassay. 
0198 Equal volumes of Griess Reagent were added to 
Supernatants to assay nitric oxide in Solution. An ELISA plate 
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reader was used to read absorbance. Infected macrophages 
secreted less nitric oxide than the uninfected macrophages. 
However, higher levels of nitric oxide produced by the A35A 
mutant treatment Suggests that the presence of the A35R 
protein inhibits secretion of nitric oxide in infected macroph 
ages. Thus, the presence of A35R in macrophages is associ 
ated with inhibiting nitric oxide secretion. 
0199 Supernatants were assayed using a cytotoxic T lym 
phocyte line (CTLL-2), which proliferates based on the con 
centration of IL-2 in solution. MTS/PMS was added to mea 
Sure respiration dependent on the amount of proliferation. 
The absorbance was obtained using an ELISA plate reader. 
These studies demonstrated that macrophages infected with 
the A35A mutant stimulated T cells to secrete more IL-2 in 
solution than both uninfected and wild-type (WR) infected 
cells. This indicates that the A35R protein restricts the ability 
of macrophages to stimulate T cells. 
0200 Additional studies have not demonstrated any effect 
of A35R on 1) cytotoxic lymphocyte (CTL) killing; 2) inter 
feron-beta (IFN-B) induced Class I expression in thymocytes; 
and 3) interferon-gamma (IFN-Y) induced costimulatory mol 
ecules (B7.1 molecules) on macrophages. 
II. Virulence Activity of Poxvirus A35R Protein 
0201 Determination of Virulence in Mice. 
0202 Groups of six female BALB/c 6-week-old mice 
were anesthetized and intranasally challenged with 10 to 10° 
pfu of VA35A, WR, VA35-Res virus, or PBS in 20 ul of 10 mM 
Tris-HCl (pH 9.0). Virus titers were determined on the day of 
challenge to confirm virus dose. Individual mice were 
Virus 
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weighed every two days to monitor health, and mice were 
sacrificed if they lost 30% of their body weight. 
0203. In a second experiment, mice were challenged with 
10 and 10 pfu and weighed as described. 
0204. The VA35A Mutant Virus is Attenuated in Mice. 
0205 Over the course of the experiment (14 days), mice 
challenged with PBS or VA35A gained between 10-11% in 
body weight, whereas mice challenged with 10 pful of the 
VA35-Res or VV strain WR lost, on average, 16% and 26% of 
their body weight, respectively, by day 10. Two WR-chal 
lenged mice (and no others) died between days 9 and 11. This 
experiment was repeated and attenuation of the VA35A was 
also seen at higher challenge doses. At 10 pfu, one mouse 
challenged with VA35A died, compared to four with WR and 
six with VA35-Res. When challenged with 10 pfu, all mice 
died, but survival was increased by one to two days in the 
VA35A mice. With WR, two mice died on day 6 and four mice 
died on day 7. When challenged with VA35-Res, all six mice 
died on day 6; but with VA35A, four mice died on day 7 and 
two survived until day 8. These data indicate that the A35R 
protein is important for virulence in mice. 
0206 Although the present process has been described 
with reference to specific details of certain embodiments 
thereof, it is not intended that such details should be regarded 
as limitations upon the scope of the invention except as and to 
the extent that they are included in the accompanying claims. 
0207. Throughout this application, various patents and 
non-patent publications are referenced. The disclosures of 
these patents and publications in their entireties are hereby 
incorporated by reference into this application in order to 
more fully describe the state of the art to which this invention 
pertains. 
TABLE 1 
Viral Orthologous Clusters V2.0 (VOCS) 
Vaccinia virus (Tian Tan) 
Lumpy skin disease virus (Neethling 
Warmbaths LW) 
Lumpy skin disease virus (Neethling 
vaccine LW 1959) 
Fowlpox virus (HP1-438 Munich) 
Orf virus (NZ2- Sequence 1 
from Patent WOO3006654) 
Camelpox virus CMS (CMS) 
Sheeppox virus (A) 
Sheeppox virus (NISKHI) 
Goatpox virus (G20-LKV) 
Orf virus (OV-IA82) 
Rabbitpox virus (Utrecht) 
Vaccinia virus (Acambis 3000 Modified 
Virus Ankara (MVA)) 
Monkeypox Virus Walter Reed 267 
Vaccinia virus (LC16m8) 
Vaccinia virus (Lister) 
Vaccinia virus (LC16mO) 
Deerpox virus (W-1170-84) 
Monkeypox virus (Sierra Leone) 
Monkeypox virus (COP-58) 
Monkeypox virus (USA 2003 044) 
Monkeypox virus (Congo 2003. 358) 
Monkeypox virus (Zaire 1979-005) 
Monkeypox virus (Liberia 1970 184) 
Monkeypox virus (USA 2003 039) 
Orf virus (NZ2) 
Variola major virus (Bangladesh-1975) 
Virus data 




















MPXV-USA 2003 044 DQ011153 
MPXV-Congo 2003 358 DQ01 1154 
MPXV-Zaire 1979 005 DQ011155 
MPXV-Liberia 1970 184 DQ011 156 




US 2012/O294.896 A1 
TABLE 1-continued 





MPXV COP-141 59858947 
MPXV SL-141 S8220611 
MPXV. 68448826 
USA 2003 O44 
55 
MPXV. 68449229 
Zaire 1979 005 
55 
MPXV. 68449027 
Congo 2003. 358 
55 
MPXV. 68449428 
Liberia 1970 184 
55 
MPXV. 684496.28 








USA 2003 044 
MPXV. 
Zaire 1979 010454145 
MPXV. 
Congo 2003 315484176 
MPXV. 
Liberia 1970 114844596 
MPXV. 

































































































































YLDW-124R - - - - - - ATAATTTTA--TAATTAS 
Differences & 
YMTW-124R --ATGTATAATGTG. --TTATTA:TTE 
Scale 8O 
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MPXV-Congo 2003 358-155 A. 
Differences 
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CAGATAT- - - - - - AGAAGGTAAA3ATSAG 
CAETAAT------ TSATGAAAAAGAASAA CAGTT 
ATT CASTAA) 
















CATSATSTTAGATAT . . . . . . ASAAgSTAAAEATSAA 



















CATSATGTTAGATAT- - - - - - AGAASATAAASA 
CATSATSTTAGATAT------ ASAAGATAAAEATSA 
CAT:ATSTTAGATAT- - - - - - ASAAGATAAAEATS: 
CAT:AT3TTAGATAT- - - - - - AGAASATAAASA 
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CAT:ATAA- - - - - - - - - - - - - - - - - 
CAT&ATAA- - - - - - - - - - - - - - - - - 
  
  


















































in Table 2: 
8- 155 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
BPSV, Bovine popular stomatitis virus (SEQD NO:8) 
CMLV, Camelpox virus (SEQ ) NO:9) 
CPXV, Cowpox virus (SEQID 
DPV. Deerpox virus (SEQD 
NO; 10) 
O: 11) 
ECTV, Ectromelia virus (SEQ ) NO. 12) 
GTPV. Goatpox virus Pellor (S EQID NO: 13) 
LSDV, Lumpy skin disease virus (SEQID NO: 14) 
MOCV, Molluscum contagiosum virus (SEQD NO:15) 
MPXV. Monkeypox virus (SEQID NOs: 16, 17 and 18) 
MYXV. Myxoma virus (SEQ ) NO; 19) 
ORFV, Orf virus (SEQD NO: 20) 
RPXV. Rabbitpox virus (SEQ ) NO: 21) 
SFV, Rabbit fibroma virus (SEQID NO: 22) 
SPPV. Sheeppox virus (SEQID NO. 23) 
SWPV. Swinepox virus (SEQ 
VACV. Vaccinia virus (SEQID 
D NO; 24) 
NOS: 25, 26, 27, 28 and 29) 
YLDV, Yaba-like disease virus (SEQID NO:30) 
YMTV, Yaba-like monkey tumor virus (SEQID NO:31) 
29 
TABLE 2-continued 
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TABLE 3-continued 
In Table 3 
BPSV.Bovine popular stomatitis virus (SEQ 
DPV. Deerpox virus (SEQID NO:33) 
LSDV, Lumpy skin disease virus (SEQID NO:34) 
MOCV, Molluscum contagiosum virus (SEQD NO:35) 
MYXV. Myxoma virus (SEQID NO:36) 
ORFV, Orf virus (SEQD NO:37) 
SPPV Sheeppox virus (SEQID NO:38) 
SWPV. Swinepox virus (SEQID NO:39) 
VACV. Vaccinia virus (SEQID NO: 40) 
VARY. Variola virus (SEQD NO:41) 
YLDV, Yaba-like disease virus (SEQID NO: 42) 
YMTV, Yaba-like monkey tumor virus (SEQID NO:43) 
D NO:32) 
SEQUENCE LISTING 
<16O is NUMBER OF SEO ID NOS: 44 
<210s, SEQ ID NO 1 
&211s LENGTH: 528 
&212s. TYPE: DNA 
<213> ORGANISM: Waccinia virus 
<4 OOs, SEQUENCE: 1 
atggacgc.cg cqtttgtt at tactic caatig gotgttgttga citata acaga tacattgtat 6 O 
gatgatctog at atttcaat catggactitt ataggaccat acattatagg taacataaaa 12 O 
actgtc.caaa tagatgtacg ggatataaaa tatt cogaca togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagc 24 O 
atttgttgc.cg catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
ttagatatag aagataaa.ca totago cattt tat ct attcc catctattga tigtttittaac 360 
gctacaatca tagaag.cgta taacctgt at acagotggag attat catct aat catcaat 42O 
cctt cagata atctgaaaat gaaattgtcg tittaattictt cattctgcat atcagacggc 48O 
aatggatgga ttataattga tigggaaatgc aatagtaatt ttittatca 528 
<210s, SEQ ID NO 2 
&211s LENGTH: 176 
212. TYPE: PRT 
<213> ORGANISM: Waccinia virus 
<4 OOs, SEQUENCE: 2 
Met Asp Ala Ala Phe Val Ile Thr Pro Met Gly Val Lieu. Thir Ile Thr 
1. 5 1O 15 
Asp Thir Lieu. Tyr Asp Asp Lieu. Asp Ile Ser Ile Met Asp Phe Ile Gly 
2O 25 3O 
Pro Tyr Ile Ile Gly Asn. Ile Llys Thr Val Glin Ile Asp Val Arg Asp 
35 4 O 45 
Ile Llys Tyr Ser Asp Met Gln Lys Cys Tyr Phe Ser Tyr Lys Gly Lys 
SO 55 6 O 
Ile Val Pro Glin Asp Ser Asn Asp Lieu Ala Arg Phe Asn. Ile Tyr Ser 
65 70 7s 8O 
Ile Cys Ala Ala Tyr Arg Ser Lys Asn. Thir Ile Ile Ile Ala Cys Asp 
85 90 95 
Tyr Asp Ile Met Lieu. Asp Ile Glu Asp Llys His Glin Pro Phe Tyr Lieu. 
1OO 105 11 O 
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Phe Pro Ser Ile Asp Val 
115 
Lieu. Tyr Thr Ala Gly Asp 
13 O 
Lieu Lys Met Lys Lieu. Ser 
145 150 
Asn Gly Trp Ile Ile Ile 
1.65 
<210s, SEQ ID NO 3 
&211s LENGTH: 60 
212. TYPE: PRT 
<213> ORGANISM: Wariola 
<4 OOs, SEQUENCE: 3 
Met Asp Thir Thr Phe Val 
1. 5 
Asp Thir Lieu. Tyr Asp Asp 
2O 
Pro Tyr Ile Ile Gly Asn 
35 
Ile Llys Tyr Ser Asp Met 
SO 
<210s, SEQ ID NO 4 
&211s LENGTH: 60 
212. TYPE: PRT 
<213> ORGANISM: Wariola 
<4 OOs, SEQUENCE: 4 
Met Asp Thir Thr Phe Val 
1. 5 
Asp Thir Lieu. Tyr Asp Asp 
2O 
Pro Tyr Ile Ile Gly Asn 
35 
Ile Llys Tyr Ser Asp Met 
SO 
<210s, SEQ ID NO 5 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artifici 








































































<223> OTHER INFORMATION: Example PCR primer 
<4 OOs, SEQUENCE: 5 
atggacgc.cg cgtttgtt at ta 
<210s, SEQ ID NO 6 
&211s LENGTH: 18 
&212s. TYPE: DNA 
<213> ORGANISM: Artifici 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Example PCR primer sequence 

































Ala Tyr Asn 
Ser Asp Asn 
Ser Asp Gly 
160 
Phe Lieu. Ser 
17s 
Thir Ilie Thr 
15 
Phe Ile Gly 
3O 
Val Arg Asp 
Thir Ilie Thr 
15 
Phe Ile Gly 
3O 
Val Arg Asp 
22 
18 
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34 
- Continued 
gatgat ctitg at atct caat catgg actitt at aggaccat acat catagg taa cataaaa 12 O 
actgtc.caaa tagatgtacg ggatataaaa tatt cogata togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagc 24 O 
atttgttgctg catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
ttagatatag aaggtaaa.ca totago cattt tat ct attcc catctattga tigtttittaac 360 
gctacaatca tagaag.cgta taacctgtac acagotggag attat catct gat catcaat 42O 
cctt cagatg atctgaaaat gaaattgtcg tittaattictt cattctgitat atcagacggc 48O 
aatggatgga t cataattga tigggaaatgc aatagtaatt ttittat cata a 531 
<210s, SEQ ID NO 11 
&211s LENGTH: 546 
&212s. TYPE: DNA 
<213> ORGANISM: Deerpox virus 
<4 OOs, SEQUENCE: 11 
atggaggaag attittacaac attgttaact gttittaggaa citatgagaat taaaataag 6 O 
aatctoataa aaacctatga tigatttgggt ataaacattgttgatgattt togg acccitat 12 O 
aaactic goat ctittggaaat ttctittagtt tott cagaat tdttaaaaac ctatoattta 18O 
caggattgtt atatagocca taatggaatt gtgttacatt gttcttctga taataaatta 24 O 
aatataccgg tatataaagt g tatt ctdta tatatgtcta agaaaag.cat aattatttgt 3OO 
tittgatgaat gtccaaaatt gtttatagat ggaaaatcto aacct ttcta tattittatct 360 
tott cattaa tdatggatgc gcatattatt gaagtgtata atttatatga tigagggtgat 42O 
tat cat atta ttittaaac cc ttcaaaaaat tittctaaaat atataagtga tagattittat 48O 
titatgtttaa tag acaaaaa toggttgggct attgc.cgatg gaaaagtgaa attaaatatt 54 O 
aattaa. 546 
<210s, SEQ ID NO 12 
&211s LENGTH: 531 
&212s. TYPE: DNA 
<213> ORGANISM; Ectromelia virus 
<4 OOs, SEQUENCE: 12 
atggacgc.cg cqtttgtt at tactic caatig gotgttgttga citata acaga tacattatat 6 O 
gaggat ct cq atat ct caat aatagactitt at aggaccat at attatagg taa cataaaa 12 O 
actgtc.caaa tagatgitatg ggatataaaa tatt cogaca togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagc 24 O 
atttgttgcag catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
ttagatatag aaggtaaa.ca totago cattt tat ct attcc catctattga tigtttittaac 360 
gctacaatca tagaag.cgta taatctgt at acagotggag attat catct gat catcaat 42O 
cctt cagatg atctgaaaat gaaattgttgtttaattictt cattctgcat atcagacggc 48O 
aatggatggc ticataattga tigggaaatgc aatagtaatt ttittat cata a 531 
<210s, SEQ ID NO 13 
&211s LENGTH: 576 
&212s. TYPE: DNA 
<213> ORGANISM: Goatpox virus Pellor 
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- Continued 
gagtgc.ccgc tict cqc.gctt C cqct tcgcg Ctgcctt.cgt. c9ccgc.gc.gc gaacgc.gc.cg 6OO 
Ccagcc acgc cqc.cggcc.gc gtggcc.gctic gagcgat cac aaacgc.cggc ggaaacgctg 660 
ttgcc.gc.ccg cgc.gc.ccgct cago.cgc.cg aaactgaaat aa 7 O2 
<210s, SEQ ID NO 16 
&211s LENGTH: 531 
&212s. TYPE: DNA 
<213> ORGANISM: Monkeypox virus 
<4 OOs, SEQUENCE: 16 
atggacgc.cg cqtttgtt at tactic caatig gotgttgttga citata acaga tacattgtat 6 O 
gatgat ct cq atat ct caat catgg actitt at aggaccat acattatagg taa cataaaa 12 O 
attgtc.caaa tagatgcacg ggatataaaa tatt cogaca togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagt 24 O 
atttgtaccg catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
ttagatatag aaggtaaa.ca totalaccattt tat ct attcc catctattga tigtttittaac 360 
gctacaatca tagaag.cgta taatctgt at acagotggag attat catct gat catcaat 42O 
cctt cagata atctgaaaat gaaattgtcg tittaattictt cattttgtat atcagacggc 48O 
aatggatgga ttataattga tigggaaatgt aatagtaatt ttittat cata a 531 
<210s, SEQ ID NO 17 
&211s LENGTH: 531 
&212s. TYPE: DNA 
<213> ORGANISM: Monkeypox virus 
<4 OOs, SEQUENCE: 17 
atggacgc.cg cqtttgtt at tactic caatig gotgttgttga citata acaga tacattgtat 6 O 
gatgat ct cq atat ct caat catgg actitt at aggaccat acattatagg taa cataaaa 12 O 
attgtc.caaa tagatatacg ggatataaaa tatt cogaca togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagt 24 O 
atttgtaccg catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
ttagatatag aaggtaaa.ca totalaccattt tat ct attcc catctattga tigtttittaac 360 
gctacaatca tagaag.cgta taatctgt at acagotggag attat catct gat catcaat 42O 
cctt cagata atctgaaaat gaaattgtcg tittaattictt cattttgtat atcagacggc 48O 
aatggatgga ttataattga tigggaaatgt aatagtaatt ttittat cata a 531 
<210s, SEQ ID NO 18 
&211s LENGTH: 531 
&212s. TYPE: DNA 
<213> ORGANISM: Monkeypox virus 
<4 OOs, SEQUENCE: 18 
atggacgc.cg cqtttgtt at tactic caatig gotgttgttga citata acaga tacattgtat 6 O 
gatgat ct cq atat ct caat catgg actitt at aggaccat acattatagg taa cataaaa 12 O 
attgtc.caaa tagatgcacg ggatataaaa tatt cogaca togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagt 24 O 
atttgtaccg catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
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- Continued 
atttgttgc.cg catacagat.c aaaaaatacc atcatcatca tag catgcga citatgatatic 3OO 
atgttagata tagaagataa a catcago catttitatictat tcc catctat tdatgtttitt 360 
aacgctacaa toatagaa.gc gtata acctg tatacagctg gagattatca totaatcatc 42O 
aatcct tcag ataatctgaa aatgaaattig togtttaatt citt cattctg catat cagac 48O 
ggcaatggat ggat cataat tatgggalaa to aatagta atttittt at C ataa 534 
<210s, SEQ ID NO 22 
&211s LENGTH: 540 
&212s. TYPE: DNA 
<213> ORGANISM: Rabbit fibroma virus 
<4 OOs, SEQUENCE: 22 
atggacgc.cg atagaataac gtgcgtgaca gcc ct aggcg tttgtctat acaccacgac 6 O 
gagatgalaca ttgttgttctgaactggga attacattca taggaga cat taccgitat 12 O 
cgcgtggcga ctittaaat at ttgtc.cggtg gcgttcgatg atgta catca acgtggcgtg 18O 
attaactgtt at atcgtcag tdatggaagg attatacgat gttctaacca gtacaggcta 24 O 
gcattt coca tacacaaggit atatacggtg tataaatcta ttaatagittt tatgttttgt 3OO 
tittgataaat gtttcaaatt acacatagat accaaccacc aagattt citt cattacgt.ca 360 
tctatagcga t t caggatgc acgagt cctt galagtgtaca acctttacaa gaaaggagac 42O 
taccattt cattct caatcc cagtgatgtg ttcttaaatgttittggtaaa gaaatacaat 48O 
gtctgtttga C9tccalacac aggatgggtg atcgc.cgatg gaaaaagtga aatagaatag 54 O 
<210s, SEQ ID NO 23 
&211s LENGTH: 576 
&212s. TYPE: DNA 
<213> ORGANISM; sheeppox virus 
<4 OOs, SEQUENCE: 23 
atggattittg actt catttt caacaaagac gaggatgata tittatacgtt aataacaact 6 O 
ttaggtgt at taaaaataaa aaaaaaagaa at atcaaaag tttgtag toga act agacatt 12 O 
aattittatag aaa.cattagg accittataat gtagtat citt taaatataca cc cattt cot 18O 
aacaattitta tagaacaatc aaatttgatt aactgttata tat cittataa tdggagacitg 24 O 
titt cactgtt ctaaagatga aag actgagt atcc.caataa atggattgta tagagggittt 3OO 
tactictaata at agtttitat attitt cittitt gataaagaaa attatggitaa gttactaatt 360 
gatgaaaaaa aacaat attt ttacctaggc acagoatatg atatagittaa ttcaaatatic 42O 
atcgaagtgt ataatttata caggaaagga gattacaatt ttattataag to catcagat 48O 
aattittittaa aaatgattitc taatcaatca aaaatgtgct taactgataa aagtgggtgg 54 O 
tg tattgtgg atataaaaaa tdaaatagaa tattaa 576 
<210s, SEQ ID NO 24 
&211s LENGTH: 558 
&212s. TYPE: DNA 
<213> ORGANISM: Swinepox virus 
<4 OOs, SEQUENCE: 24 
atgitat caat ggat.cgt.cga tatggctacc tatacatt.cg taa catcatt gggtg tattg 6 O 
aaactatoag aagataatgt atcaagat.cg ttct cagatt taggcattac cattattgat 12 O 
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cgtatagg to catat catat agcatcgata gaattacatt citatt coaat ggagtatata 18O 
acacaaaaag atttagaaaa atgttatata gttcataatg gtttgatatt acaatgctict 24 O 
aaagataata atctaaatat gcatgttcat aatgtacatc gcgctitatica ttctgttaat 3OO 
agttgcat at tatgtttcga tagat atc.cg aggct tagtt tagggaala at at Caacct 360 
ttittatatat caa.cat ctac atgcattact gctaatagta taatggaagt ttata atttg 42O 
aataaaaaag atgattatga atttattata aatccatctgaaacatttat aaaacatatt 48O 
aaagaaaaat caaatatatgtttaacggat aaa catggct ggattataat cqatiggcaaa 54 O 
aatgaaatta aat attaa 558 
<210s, SEQ ID NO 25 
&211s LENGTH: 531 
&212s. TYPE: DNA 
<213> ORGANISM: Waccinia virus 
<4 OOs, SEQUENCE: 25 
atggacgc.cg cqtttgtt at tactic caatig gotgttgttga citata acaga tacattgtat 6 O 
gatgat ct cq atat ct caat catgg actitt at aggaccat acattatagg taa cataaaa 12 O 
actgtc.caaa tagatgtacg ggatataaaa tatt cogaca togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagc 24 O 
atttgttgc.cg catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
ttagatatag aagataaa.ca totago cattt tat ct attcc catctattga tigtttittaac 360 
gctacaatca tagaag.cgta taacctgt at acagotggag attat catct aat catcaat 42O 
cctt cagata atctgaaaat gaaattgtcg tittaattictt cattctgcat atcagacggc 48O 
aatggatgga t cataattga tigggaaatgc aatagtaatt ttittat cata a 531 
<210s, SEQ ID NO 26 
&211s LENGTH: 531 
&212s. TYPE: DNA 
<213> ORGANISM: Waccinia virus 
<4 OOs, SEQUENCE: 26 
atggacgc.cg cqtttgtt at tactic caatig gotgttgttga citata acaga tacattgtat 6 O 
gatgat ct cq atatttcaat catgg actitt at aggaccat acattatagg taa cataaaa 12 O 
actgtc.caaa tagatgtacg ggatataaaa tatt cogaca togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagc 24 O 
atttgttgc.cg catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
ttagatatag aagataaa.ca totago cattt tat ct attcc catctattga tigtttittaac 360 
gctacaatca tagaag.cgta taacctgt at acagotggag attat catct aat catcaat 42O 
cctt cagata atctgaaaat gaaattgtcg tittaattictt cattctgcat atcagacggc 48O 
aatggatgga ttataattga tigggaaatgc aatagtaatt ttittat cata a 531 
<210s, SEQ ID NO 27 
&211s LENGTH: 531 
&212s. TYPE: DNA 
<213> ORGANISM: Waccinia virus 
<4 OOs, SEQUENCE: 27 
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atggacgc.cg cqtttgtt at tactic caatig gotgttgttga citata acaga tacattgtat 6 O 
gatgat ct cq atat ct caat catgg actitt at aggaccat acattatagg taa cataaaa 12 O 
actgtc.caaa tagatgtacg ggatataaaa tatt cogaca togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagc 24 O 
atttgttgc.cg catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
ttagatatag aagataaa.ca totago cattt tat ct attcc catctattga tigtttittaac 360 
gctacaatca tagaag.cgta taacctgt at acagotggag attat catct aat catcaat 42O 
cctt cagata atctgaaaat gaaattgtcg tittaattictt cattctgcat atcagacggc 48O 
aatggatgga t cataattga tigggaaatgc aatagtaatt ttittat cata a 531 
<210s, SEQ ID NO 28 
&211s LENGTH: 531 
&212s. TYPE: DNA 
<213> ORGANISM: Waccinia virus 
<4 OOs, SEQUENCE: 28 
atggacgc.cg cqtttgtt at tactic caatig gotgttgttga citata acaga tacattgtat 6 O 
gatgat ct cq atat ct caat catgg actitt at aggaccat acattatagg taa cataaaa 12 O 
actgtc.caaa tagatgtacg ggatataaaa tatt cogaca togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagc 24 O 
atttgttgc.cg catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
ttagatatag aagataaa.ca totago cattt tat ct attcc catctattga tigtttittaac 360 
gctacaatca tagaag.cgta taacctgt at acagotggag attat catct aat catcaat 42O 
cctt cagata atctgaaaat gaaattgtcg tittaattictt cattctgcat atcagacggc 48O 
aatggatgga t cataattga tigggaaatgc aatagtaatt ttittat cata a 531 
<210s, SEQ ID NO 29 
&211s LENGTH: 531 
&212s. TYPE: DNA 
<213> ORGANISM: Waccinia virus 
<4 OOs, SEQUENCE: 29 
atggacgc.cg cqtttgtt at tactic caatig gotgttgttga citata acaga tacattgtat 6 O 
gatgat ct cq atat ct caat catgg actitt at aggaccat acattatagg taa cataaaa 12 O 
actgtc.caaa tagatgtacg ggatataaaa tatt cogaca togcaaaaat g c tactittagc 18O 
tataagggta aaatagttcc ticaggattct aatgatttgg ctagattcaa catttatagc 24 O 
atttgttgc.cg catacagat.c aaaaaatacc atcat catag catgcgact a tigatat catg 3OO 
ttagatatag aagataaa.ca totago cattt tat ct attcc catctattga tigtttittaac 360 
gctacaatca tagaag.cgta taacctgt at acagotggag attat catct aat catcaat 42O 
cctt cagata atctgaaaat gaaattgttgtttaattictt cattctgcat atcagacggc 48O 
aatggatgga t cataattga tigggaaatgc aatagtaatt ttittat cata a 531 
<210s, SEQ ID NO 3 O 
&211s LENGTH: 540 
&212s. TYPE: DNA 
<213> ORGANISM: Yaba-like disease virus 
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<4 OOs, SEQUENCE: 30 
atggaaatcg ccggittataa ttittataatt actt catttg gagtaataaa aatacat agt 6 O 
gtaaat catt ttalagactgt atgtgaggat ttaggcatcg ttattgttga citatataggit 12 O 
gaatacgcaa tag.cgacgtt agaagttcaa gaaataaatg taaac ctitat taaccaaaat 18O 
gatatatacg attgttacgt agcgtgtaat gigttittatag taaactgttc taagttaaat 24 O 
aatgttcc.gt titc.ccgtaac acaggtatat tatgcatttic ttacaaaaaa caaaat atta 3OO 
titatgttgcg ataaat atco aaaactatica ataaacaata aaatacagoc attittacatt 360 
tottct tcca tttacatatt agaatcaaaa at attagaag tt cataactt atataataaa 42O 
ggagattatc actittata at taatcctt cq accatttitt taatgtttitt aggaaaaatg 48O 
gtta acttitt gtttaactga caaaaatggg toggattatag togatgtaaa agtgaaataa 54 O 
<210s, SEQ ID NO 31 
&211s LENGTH: 579 
&212s. TYPE: DNA 
<213> ORGANISM: Yaba monkey tumor virus 
<4 OOs, SEQUENCE: 31 
atgaaaagtt at agtgttgtt tat coacaat acgattgaaa acatgtataa tdtcgittatt 6 O 
actt catttg gagtaataaa tatatacggit tttgaacatt taaaaac cqt atgtgaagat 12 O 
ttagg tattgttgtttittga citttgtagga gag tacgc.ca togcaa.catt aaacgct caa 18O 
gaaataagcg taalaccittat tacacaagat gatataaacg actgttatat agcatgtaac 24 O 
ggttittatag taaaatgttctgagtataac aaggttc.cgt titc.ccgtaat acagatatat 3OO 
tgtgcttitt c ttacaaagag caaaattitta t tatgttgtg attat caccc aaaactgttt 360 
gtggataa.ca tdttacaa.cc gttittatatt totttcticta tttgtatatt ggaat cacga 42O 
gtattagagg tittataattt atataataag gigtgactatt at cittataat caatic ctitca 48O 
attgatttitt taacatttitt ggtaaaaacc gttagcttct gtttaactga caggaacgga 54 O 
tgggittataa ticgacgcaaa aagtgaaata atacattag st 9 
<210s, SEQ ID NO 32 
&211s LENGTH: 184 
212. TYPE: PRT 
<213> ORGANISM: Bovine papular stomatitis virus 
<4 OOs, SEQUENCE: 32 
Met Thr Asn Gly Asn Met Ser Cys Lieu. Glin Ile Lieu. Thr Pro Phe Gly 
1. 5 1O 15 
Lieu. Ile Phe Ala Pro Asp Asp Val Arg Lieu. Arg Glu Ile Ala Lieu. Glu 
2O 25 3O 
Lieu. Gly Ile Thr Tyr Val Ser Arg Ala Phe Gly Asp Met Leu Tyr Gly 
35 4 O 45 
Glu Met Ser Phe Thr Ser Leu Pro Met Asn Glu Val Pro Ala Cys Val 
SO 55 6 O 
Ser Asp Cys Tyr Lieu Ala Val Asin Gly Asn Lieu. Ile Pro Cys Thr Glu 
65 70 7s 8O 
Ser Phe Arg Lieu. Arg Ile Pro Met Asp Gly Val Lys Ala Ala Tyr Arg 
85 90 95 
Thr Gly Thr Gly Lys Thir Ile Lieu. Cys Gly Pro Glu Phe Asin Val Val 
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1OO 105 11 O 
Asn Pro Ser Gly Phe Arg Pro Ala Lieu. Arg Lieu. Arg Glu Lieu. Ser His 
115 12 O 125 
Val Ala Ala His Thr Glu Ile Lieu. Glu Lieu. Tyr Ser Glu Ser Gly Asn 
13 O 135 14 O 
Tyr Glu Phe Ile Met Gly Pro Ser Ala Arg Phe Met Thr Ser Leu Met 
145 150 155 160 
Ala Lys Glu Ser Val Cys Lieu. Phe Gly Ser Gly Trp Cys Val Val Asp 
1.65 17O 17s 
Lieu. Arg Arg Ile Ser Phe Thr Pro 
18O 
<210s, SEQ ID NO 33 
&211s LENGTH: 181 
212. TYPE: PRT 
<213> ORGANISM: Deerpox virus 
<4 OOs, SEQUENCE: 33 
Met Glu Glu Asp Phe Thr Thr Lieu. Lieu. Thr Val Lieu. Gly Thr Met Arg 
1. 5 1O 15 
Ile Glu Asn Lys Asn Lieu. Ile Llys Thr Tyr Asp Asp Lieu. Gly Ile Asn 
2O 25 3O 
Ile Val Asp Asp Phe Gly Pro Tyr Lys Lieu Ala Ser Lieu. Glu Ile Ser 
35 4 O 45 
Lieu Val Ser Ser Glu Lieu Lleu Lys Thr Tyr Asp Lieu. Glin Asp Cys Tyr 
SO 55 6 O 
Ile Ala His Asn Gly Ile Val Lieu. His Cys Ser Ser Asp Asn Llys Lieu. 
65 70 7s 8O 
Asn Ile Pro Val Tyr Lys Val Tyr Ser Val Tyr Met Ser Lys Llys Ser 
85 90 95 
Ile Ile Ile Cys Phe Asp Glu. Cys Pro Llys Lieu. Phe Ile Asp Gly Lys 
1OO 105 11 O 
Ser Glin Pro Phe Tyr Ile Leu Ser Ser Ser Leu Met Met Asp Ala His 
115 12 O 125 
Ile Ile Glu Val Tyr Asn Lieu. Tyr Asp Glu Gly Asp Tyr His Ile Ile 
13 O 135 14 O 
Lieu. Asn Pro Ser Lys Asn. Phe Lieu Lys Tyr Ile Ser Asp Arg Phe Tyr 
145 150 155 160 
Lieu. Cys Lieu. Ile Asp Lys Asn Gly Trp Ala Ile Ala Asp Gly Llys Val 
1.65 17O 17s 
Llys Lieu. Asn. Ile Asn 
18O 
<210s, SEQ ID NO 34 
&211s LENGTH: 191 
212. TYPE: PRT 
<213> ORGANISM: lumpy skin disease virus 
<4 OOs, SEQUENCE: 34 
Met Asp Phe Asp Phe Ile Phe Asp Lys Asp Glu Asp Asp Ile Tyr Thr 
1. 5 1O 15 
Lieu. Ile Thir Thir Lieu. Gly Val Lieu Lys Ile Llys Llys Lys Glu Ile Ser 
2O 25 3O 
Llys Val Cys Ser Glu Lieu. Gly Ile Asn Lieu. Ile Glu Thir Lieu. Gly Pro 
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35 4 O 45 
Tyr Asn Val Val Ser Lieu. Asn Ile His Pro Phe Pro Asn Asin Phe Ile 
SO 55 6 O 
Glu Glin Ser Asn Lieu. Ile Asn Cys Tyr Ile Ser Tyr Asn Gly Thr Lieu. 
65 70 7s 8O 
Phe His Cys Ser Lys Asp Glu Arg Lieu. Ser Ile Pro Ile Asin Gly Lieu. 
85 90 95 
Tyr Arg Gly Phe Tyr Ser Asn Asn Ser Phe Ile Phe Ser Phe Asp Llys 
1OO 105 11 O 
Glu Asn Tyr Gly Llys Lieu. Lieu. Ile Asp Glu Lys Glu Glin Tyr Phe Tyr 
115 12 O 125 
Lieu. Gly Thr Ala Tyr Asp Ile Val Asn. Ser Asn. Ile Ile Glu Val Tyr 
13 O 135 14 O 
Asn Lieu. Tyr Arg Lys Gly Asp Tyr Asn. Phe Ile Ile Asn. Pro Ser Asp 
145 150 155 160 
Asn Phe Lieu. Glu Met Ile Ala Asn Glin Ser Lys Met Cys Lieu. Thir Asp 
1.65 17O 17s 
Llys Ser Gly Trp Cys Ile Val Asp Ile Lys Asn. Glu Ile Glu Tyr 
18O 185 19 O 
<210s, SEQ ID NO 35 
&211s LENGTH: 233 
212. TYPE: PRT 
<213> ORGANISM: Molluscum contagiosum virus 
<4 OOs, SEQUENCE: 35 
Met Gly Pro Gly Gly Phe Pro Val Ile Thr Pro Leu Gly Arg Met His 
1. 5 1O 15 
Lieu. Arg Ala Asp Met Arg Thr Arg Val Met Cys Val Asp Phe Gly Val 
2O 25 3O 
Thr Met Asp Thr Lieu. Arg Val Lieu. Gly Pro Tyr Val Val Met Val Pro 
35 4 O 45 
Met Lieu. Glu Pro Ala Ser Ala Ser Lieu. Lieu Ala Pro Arg Ala Lieu. Arg 
SO 55 6 O 
Asp Cys Tyr Val Ala Ala His Gly Val Lieu. Lieu. His Cys Ser Glu Lieu 
65 70 7s 8O 
Ala Tyr Lieu. Cys Ala Pro Met Thr Arg Ile Phe Ala Val Phe Arg Ala 
85 90 95 
Arg Arg Arg Tyr Val Lieu. Cys Cys Asp Asp Tyr Asp Val Lieu. Arg Thr 
1OO 105 11 O 
His Val Gly Gly Ser Ala Phe Ser Val Arg Arg Phe Thr Asp Ala Asp 
115 12 O 125 
Phe Glu Arg Val Arg Val Lieu. Glu Lieu. Tyr Asn Tyr Asn Tyr Cys Gly 
13 O 135 14 O 
Glu Tyr Glin Lieu Val Lieu Lleu Pro Ser Val Arg Lieu. Lieu. Arg Glin Lieu. 
145 150 155 160 
Glin Ser Cys Ala Thr Tyr Cys Lieu. Asp Asp Gly His Gly Trp Lieu Ala 
1.65 17O 17s 
Val Asp Ala Cys Glu. Cys Pro Lieu. Ser Arg Phe Arg Phe Ala Lieu Pro 
18O 185 19 O 
Ser Ser Pro Arg Ala Asn Ala Pro Pro Ala Thr Pro Pro Ala Ala Trp 
195 2OO 2O5 
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Pro Leu Glu Arg Ser Glin Thr Pro Ala Glu Thir Lieu Lleu Pro Pro Ala 
21 O 215 22O 
Arg Pro Lieu. Glu Pro Pro Llys Lieu Lys 
225 23 O 
<210s, SEQ ID NO 36 
&211s LENGTH: 179 
212. TYPE: PRT 
<213> ORGANISM: Myxoma virus 
<4 OOs, SEQUENCE: 36 
Met Asp Ala Asp Arg Ile Thr Cys Val Thir Ala Lieu. Gly Val Lieu. Tyr 
1. 5 1O 15 
Ile Arg His Asp Glu Ile Asp Thr Val Arg Ser Glu Lieu. Gly Ile Thr 
2O 25 3O 
Phe Ile Gly Asp Val Gly Pro Tyr Arg Val Ala Thr Lieu. Asn. Ile Cys 
35 4 O 45 
Pro Val Ala Lieu. Asp Asp Val Tyr Glin Arg Gly Val Thr Asn. Cys Tyr 
SO 55 6 O 
Ile Val Ser Asp Gly Arg Ile Thir Arg Cys Ser Asn Glin Tyr Arg Lieu. 
65 70 7s 8O 
Thr Phe Pro Ile His Llys Val Tyr Thr Val Tyr Lys Ser Ile Asin Ser 
85 90 95 
Phe Met Lieu. Cys Phe Asp Llys Cys Phe Lys Lieu. Arg Ile Asp ASn Asn 
1OO 105 11 O 
Pro Glin Asp Phe Phe Ile Thr Ser Ser Ile Ala Ile Glin Asp Ala Arg 
115 12 O 125 
Val Lieu. Glu Val Tyr Asn Lieu. Tyr Lys Lys Gly Asp Tyr His Lieu. Ile 
13 O 135 14 O 
Lieu. Asn Pro Ser Asp Ala Phe Lieu. Asn Gly Lieu Val Llys Llys Tyr Asn 
145 150 155 160 
Val Cys Lieu. Ser Ser Asn Thr Gly Trp Val Ile Ala Asp Gly Lys Ser 
1.65 17O 17s 
Glu Ile Glu 
<210s, SEQ ID NO 37 
&211s LENGTH: 179 
212. TYPE: PRT 
<213> ORGANISM: Orf virus 
<4 OO > SEQUENCE: 37 
Met Ser Arg Lieu. Glin Ile Lieu. Thir Ser Phe Gly Glin Ile Phe Ala Pro 
1. 5 1O 15 
Asp Glu Ala Arg Lieu. Arg Glu Ile Ala Arg Asp Lieu. Gly Ile Cys Thr 
2O 25 3O 
Ile Lys Arg Ala Phe Gly Asp Met Lieu. Tyr Gly Phe Ile Asp Phe Asp 
35 4 O 45 
Pro Val Pro Leu. Thr Glin Val Asn Met Leu Met Ser Asn Cys Tyr Phe 
SO 55 6 O 
Ala Val Asin Gly Asn Lieu Lleu Pro Cys Thr Glu Asp Phe Arg Lieu. Arg 
65 70 7s 8O 
Lieu Pro Ala Thr Glu Ile Ser Ala Ala Tyr Lieu. Thir Arg Thr Gly Arg 
85 90 95 
Thir Ile Lieu. Cys Gly Lys Asp Phe Asin Ile Val Ala Pro Ser Gly Phe 
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1OO 105 11 O 
Llys Pro Ser Met Arg Lieu. Arg Asp Lieu. Ser His Val Ser Ala Lieu Val 
115 12 O 125 
Glu Ile Lieu. Glu Val Tyr Asp Glu Ser Gly Glu Tyr Glin Phe Val Lieu. 
13 O 135 14 O 
Gly Pro Ser Ala Glin Phe Met Lieu. Arg Lieu Met Glu Lys Glu Asn. Wall 
145 150 155 160 
Cys Lieu. Phe Gly Ser Gly Trp Cys Ile Val Asp Lieu. Arg Llys Lieu. Asp 
1.65 17O 17s 
Wall Pro Ile 
<210s, SEQ ID NO 38 
&211s LENGTH: 191 
212. TYPE: PRT 
<213> ORGANISM; sheeppox virus 
<4 OOs, SEQUENCE: 38 
Met Asp Phe Asp Phe Ile Phe Asn Lys Asp Glu Asp Asp Ile Tyr Thr 
1. 5 1O 15 
Lieu. Ile Thir Thir Lieu. Gly Val Lieu Lys Ile Llys Llys Lys Glu Ile Ser 
2O 25 3O 
Llys Val Cys Ser Glu Lieu. Asp Ile Asin Phe Ile Glu Thir Lieu. Gly Pro 
35 4 O 45 
Tyr Asn Val Val Ser Lieu. Asn Ile His Pro Phe Pro Asn Asin Phe Ile 
SO 55 6 O 
Glu Glin Ser Asn Lieu. Ile Asn. Cys Tyr Ile Ser Tyr Asn Gly Arg Lieu. 
65 70 7s 8O 
Phe His Cys Ser Lys Asp Glu Arg Lieu. Ser Ile Pro Ile Asin Gly Lieu. 
85 90 95 
Tyr Arg Gly Phe Tyr Ser Asn Asn Ser Phe Ile Phe Ser Phe Asp Llys 
1OO 105 11 O 
Glu Asn Tyr Gly Llys Lieu. Lieu. Ile Asp Glu Lys Lys Glin Tyr Phe Tyr 
115 12 O 125 
Lieu. Gly Thr Ala Tyr Asp Ile Val Asn. Ser Asn. Ile Ile Glu Val Tyr 
13 O 135 14 O 
Asn Lieu. Tyr Arg Lys Gly Asp Tyr Asn. Phe Ile Ile Ser Pro Ser Asp 
145 150 155 160 
Asn Phe Lieu Lys Met Ile Ser Asn Glin Ser Lys Met Cys Lieu. Thir Asp 
1.65 17O 17s 
Llys Ser Gly Trp Cys Ile Val Asp Ile Lys Asn. Glu Ile Glu Tyr 
18O 185 19 O 
<210s, SEQ ID NO 39 
&211s LENGTH: 185 
212. TYPE: PRT 
<213> ORGANISM: Swinepox virus 
<4 OOs, SEQUENCE: 39 
Met Tyr Gln Trp Ile Val Asp Met Ala Thr Tyr Thr Phe Val Thr Ser 
1. 5 1O 15 
Lieu. Gly Val Lieu Lys Lieu. Ser Glu Asp Asn Val Ser Arg Ser Phe Ser 
2O 25 3O 
Asp Lieu. Gly Ile Thir Ile Ile Asp Arg Ile Gly Pro Tyr His Ile Ala 
35 4 O 45 
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Ser Ile Glu Lieu. His Ser Ile Pro Met Glu Tyr Ile Thr Glin Lys Asp 
SO 55 6 O 
Lieu. Glu Lys Cys Tyr Ile Val His Asn Gly Lieu. Ile Lieu. Glin Cys Ser 
65 70 7s 8O 
Lys Asp Asn. Asn Lieu. Asn Met His Val His Asn. Wal His Arg Ala Tyr 
85 90 95 
His Ser Val Asn. Ser Cys Ile Lieu. Cys Phe Asp Arg Tyr Pro Arg Lieu. 
1OO 105 11 O 
Ser Lieu. Glu Gly Lys Tyr Gln Pro Phe Tyr Ile Ser Thr Ser Thr Cys 
115 12 O 125 
Ile Thr Ala Asn. Ser Ile Met Glu Val Tyr Asn Lieu. Asn Llys Lys Asp 
13 O 135 14 O 
Asp Tyr Glu Phe Ile Ile Asn Pro Ser Glu Thir Phe Ile Llys His Ile 
145 150 155 160 
Lys Glu Lys Ser Asn. Ile Cys Lieu. Thir Asp Llys His Gly Trp Ile Ile 
1.65 17O 17s 
Ile Asp Gly Lys Asn. Glu Ile Llys Tyr 
18O 185 
<210s, SEQ ID NO 4 O 
&211s LENGTH: 176 
212. TYPE: PRT 
<213> ORGANISM: Waccinia virus 
<4 OOs, SEQUENCE: 4 O 
Met Asp Ala Ala Phe Val Ile Thr Pro Met Gly Val Lieu. Thir Ile Thr 
1. 5 1O 15 
Asp Thir Lieu. Tyr Asp Asp Lieu. Asp Ile Ser Ile Met Asp Phe Ile Gly 
2O 25 3O 
Pro Tyr Ile Ile Gly Asn. Ile Llys Thr Val Glin Ile Asp Val Arg Asp 
35 4 O 45 
Ile Llys Tyr Ser Asp Met Gln Lys Cys Tyr Phe Ser Tyr Lys Gly Lys 
SO 55 6 O 
Ile Val Pro Glin Asp Ser Asn Asp Lieu Ala Arg Phe Asn. Ile Tyr Ser 
65 70 7s 8O 
Ile Cys Ala Ala Tyr Arg Ser Lys Asn. Thir Ile Ile Ile Ala Cys Asp 
85 90 95 
Tyr Asp Ile Met Lieu. Asp Ile Glu Asp Llys His Glin Pro Phe Tyr Lieu. 
1OO 105 11 O 
Phe Pro Ser Ile Asp Val Phe Asn Ala Thr Ile Ile Glu Ala Tyr Asn 
115 12 O 125 
Lieu. Tyr Thr Ala Gly Asp Tyr His Lieu. Ile Ile ASn Pro Ser Asp Asn 
13 O 135 14 O 
Lieu Lys Met Lys Lieu. Ser Phe Asin Ser Ser Phe Cys Ile Ser Asp Gly 
145 150 155 160 
Asn Gly Trp Ile Ile Ile Asp Gly Lys Cys Asn. Ser Asn. Phe Lieu. Ser 
1.65 17O 17s 
<210s, SEQ ID NO 41 
&211s LENGTH: 60 
212. TYPE: PRT 
<213> ORGANISM: Wariola virus 
<4 OOs, SEQUENCE: 41 













Thir Phe Wall 
5 
Tyr Asp Asp 
Ile Gly Asn 
Ser Asp Met 
<210s, SEQ ID NO 42 
&211s LENGTH: 
212. TYPE : 
<213> ORGANISM: Yaba-like disease virus 
PRT 
<4 OOs, SEQUENCE: 































































<210s, SEQ ID NO 43 
&211s LENGTH: 
212. TYPE : 
<213> ORGANISM: Yaba monkey 
PRT 
<4 OOs, SEQUENCE: 
Met Lys Ser Tyr 
1. 
Asn. Wal Wall 
His Lieu Lys 
35 

























































































































































Lieu. Thir Ile Thr 
15 
Asp Phe Ile Gly 
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48 
- Continued 
Asn Lieu. Ile Thr Glin Asp Asp Ile Asn Asp Cys Tyr Ile Ala Cys Asn 
65 70 7s 8O 
Gly Phe Ile Val Lys Cys Ser Glu Tyr Asn Llys Val Pro Phe Pro Val 
85 90 95 
Ile Glin Ile Tyr Cys Ala Phe Lieu. Thir Lys Ser Lys Ile Lieu. Lieu. Cys 
1OO 105 11 O 
Cys Asp Tyr His Pro Llys Lieu Phe Val Asp Asn Met Leu Glin Pro Phe 
115 12 O 125 
Tyr Ile Ser Phe Ser Ile Cys Ile Leu Glu Ser Arg Val Lieu. Glu Val 
13 O 135 14 O 
Tyr Asn Lieu. Tyr Asn Lys Gly Asp Tyr Tyr Lieu. Ile Ile Asin Pro Ser 
145 150 155 160 
Ile Asp Phe Lieu. Thr Phe Leu Val Lys Thr Val Ser Phe Cys Lieu. Thr 
1.65 17O 17s 
Asp Arg Asin Gly Trp Val Ile Ile Asp Ala Lys Ser Glu Ile Ile His 
18O 185 19 O 
<210s, SEQ ID NO 44 
&211s LENGTH: 15 
212. TYPE: PRT 
<213> ORGANISM: Wariola virus 
<4 OOs, SEQUENCE: 44 
Tyr Asp Asp Lieu. Asp Ile Ser Ile Met Asp Phe Ile Gly Pro Tyr 
1. 5 1O 15 
What is claimed is: 
1. A method of modulating an immune response in a Sub 
ject, comprising administering to the Subject an effective 
amount of an A35R protein or active fragment thereof of 
vaccinia virus or other poxvirus. 
2-29. (canceled) 
